{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Text Mining for Stock Prediction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Data extraction:\n",
    "\n",
    "With Seppe's code we can download any type of filing from the SEC. He included a function to get a summary for 424b5 filings, but we have to define the function to parse the main contents. \n",
    "\n",
    "We should consolidate: \n",
    "* Publication date\n",
    "* Main extracts from the publication\n",
    "* Closing stock price before the publication\n",
    "* Closing(or opening?) stock price of after the publication was filed\n",
    "\n",
    "### To do: \n",
    "* Define how to parse the main contents \n",
    "* Define a function that applies the parsing functions to the respective form types\n",
    "* Scrape financial data (Melek & Anna)\n",
    "* Join scraped info for fine-tuning\n",
    "\n",
    "\n",
    "## BERT \n",
    "Original repository: https://github.com/google-research/bert\n",
    "\n",
    "### Pre-training\n",
    "* We have to determine the corpus on which we are going to pre-train BERT\n",
    "* We need separate sentences for the NSP task, and we need to tokenize the sentences for the MLM task (see https://github.com/google-research/bert/blob/master/create_pretraining_data.py)\n",
    "* In the text file we are going to feed into Bert, the text should be one sentence per line, and there should be empty lines to denote different documents.\n",
    "\n",
    "### Fine-tuning\n",
    "For fine-tuning Bert for our particular classification task, we are going to set-up an additional layer that is going to take in the text files and predicts whether the stock price of the company (should we denote which company filed what?) that filed a particular publication is going to increase, decrease or remain stable.\n",
    "\n",
    "#### Requirements:\n",
    "* Publication date\n",
    "* Sentences regarding the risk factors\n",
    "* Closing stock price before publication date\n",
    "* Opening stock price after publication date\n",
    "* Label (e.g. increase, decrease, stable)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "from bs4 import NavigableString\n",
    "from htmllaundry import sanitize\n",
    "from htmllaundry.cleaners import LaundryCleaner\n",
    "import htmllaundry.utils\n",
    "import xmltodict\n",
    "import re\n",
    "import json\n",
    "from pprint import pprint\n",
    "import pandas as pd\n",
    "from glob import glob\n",
    "from cachecontrol import CacheControl\n",
    "from IPython.display import HTML\n",
    "import unicodedata\n",
    "from bs4 import Comment"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " # Scraping SEC filings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "sess = requests.session()\n",
    "cach = CacheControl(sess)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.display import HTML\n",
    "\n",
    "def window(html):\n",
    "    s = '<script type=\"text/javascript\">'\n",
    "    s += 'var win = window.open(\"\", \"\", \"toolbar=no, location=no, directories=no, status=no, menubar=no, scrollbars=yes, resizable=yes, width=780, height=200, top=\"+(screen.height-400)+\", left=\"+(screen.width-840));'\n",
    "    s += 'win.document.body.innerHTML = \\'' + html.replace(\"\\n\",'\\\\n').replace(\"'\", \"\\\\'\") + '\\';'\n",
    "    s += '</script>'\n",
    "    return HTML(s)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cleaning SEC encoding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "CustomCleaner = LaundryCleaner(\n",
    "            page_structure=False,\n",
    "            remove_unknown_tags=False,\n",
    "            allow_tags=['blockquote', 'a', 'i', 'em', 'p', 'b', 'strong',\n",
    "                        'h1', 'h2', 'h3', 'h4', 'h5', \n",
    "                        'ul', 'ol', 'li', \n",
    "                        'sub', 'sup',\n",
    "                        'abbr', 'acronym', 'dl', 'dt', 'dd', 'cite',\n",
    "                        'dft', 'br', \n",
    "                        'table', 'tr', 'td', 'th', 'thead', 'tbody', 'tfoot'],\n",
    "            safe_attrs_only=True,\n",
    "            add_nofollow=True,\n",
    "            scripts=True,\n",
    "            javascript=True,\n",
    "            comments=True,\n",
    "            style=True,\n",
    "            links=False,\n",
    "            meta=True,\n",
    "            processing_instructions=False,\n",
    "            frames=True,\n",
    "            annoying_tags=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "## The SEC is encoded in CP1252, and it is recommended to use UTF-8 always.\n",
    "##see: https://www.w3.org/International/questions/qa-what-is-encoding\n",
    "###### https://www.w3.org/International/articles/definitions-characters/#unicode\n",
    "###### https://www.w3.org/International/questions/qa-choosing-encodings\n",
    "\n",
    "def reformat_cp1252(match):\n",
    "    codePoint = int(match.group(1))\n",
    "    if 128 <= codePoint <= 159:\n",
    "        return bytes([codePoint])\n",
    "    else:\n",
    "        return match.group()\n",
    "\n",
    "def clean_sec_content(binary):\n",
    "    return re.sub(b'&#(\\d+);', reformat_cp1252, binary, flags=re.I).decode(\"windows-1252\").encode('utf-8').decode('utf-8')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "## this is to normalize urls\n",
    "def slugify(value):\n",
    "    value = unicodedata.normalize('NFKD', value).encode('ascii', 'ignore').decode('ascii')\n",
    "    value = re.sub('[^\\w\\s\\.\\-]', '-', value).strip().lower()\n",
    "    value = re.sub('[-\\s]+', '-', value)\n",
    "    return value"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cleaning html"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_html(file):\n",
    "    with open(file, 'r') as f: return f.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_html(html):\n",
    "    soup = BeautifulSoup(html)\n",
    "    if not soup.find('p'):\n",
    "        for div in soup.find_all('div'):\n",
    "            div.name = 'p'\n",
    "    for b in soup.find_all('b'):\n",
    "        b.name = 'strong'\n",
    "    for f in soup.find_all('font', style=re.compile('font-weight:\\s*bold')):\n",
    "        f.name = 'strong'\n",
    "    for footer in soup.find_all(class_=['header', 'footer']): \n",
    "        try: footer.decompose()\n",
    "        except: pass\n",
    "    san = sanitize(str(soup), CustomCleaner)\n",
    "    soup = BeautifulSoup(san)\n",
    "    def decompose_parent(el, parent='p', not_grandparent='table'):\n",
    "        try:\n",
    "            parent = el.find_parent(parent)\n",
    "        except: parent = None\n",
    "        if not parent: return\n",
    "        grandparent = parent.find_parent('table')\n",
    "        if grandparent: return\n",
    "        parent.decompose()\n",
    "    for el in soup.find_all(text=lambda x: 'table of contents' == str(x).lower().strip()):\n",
    "        decompose_parent(el, 'a')\n",
    "    for el in soup.find_all(text=re.compile(r'^\\s*S\\-(\\d+|[ivxlcdm]+)\\s*$')): \n",
    "        decompose_parent(el, 'p')\n",
    "    for el in soup.find_all(text=re.compile(r'^\\s*\\d+\\s*$')): \n",
    "        decompose_parent(el, 'p')\n",
    "    return soup"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Defining helper functions to download files"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def pagination_provider_by_element_start_count(find_args, find_kwargs):\n",
    "    def pagination_provider_by_element_start_count_wrapped(soup, params):\n",
    "        if soup.find(*find_args, **find_kwargs) is None: \n",
    "            return None\n",
    "        params['start'] += params['count'] \n",
    "        return params\n",
    "    return pagination_provider_by_element_start_count_wrapped"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "def params_provider_by_dict(params):\n",
    "    return lambda : params"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "## look for a table, converts it to text and removes line breaks\n",
    "def table_provider_by_summary(summary, header=0, index_col=0):\n",
    "    return lambda soup: pd.read_html(\n",
    "        str(soup.find('table', summary=summary)).replace('<br>', '<br>\\n'), header=header, index_col=index_col)[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_sec_table(url,\n",
    "                  table_provider=None,\n",
    "                  base_params={}, \n",
    "                  params_provider=None,\n",
    "                  pagination_provider=None,\n",
    "                  replace_links=True,\n",
    "                  session=None):\n",
    "    ### this function returns a tuple of a df with the respective soup element\n",
    "    def return_data_frame(session, url, params, provider):\n",
    "        request = session.get(url, params=params)\n",
    "        soup = BeautifulSoup(request.text)\n",
    "        if replace_links:\n",
    "            for a in soup.find_all('a'):\n",
    "                parent = a.find_parent('td')\n",
    "                if parent: parent.string = a['href']\n",
    "        df = provider(soup)\n",
    "        return df, soup\n",
    "    ####################################################################\n",
    "    ###if no Session, then we use the base_url to do the pull request###\n",
    "    ####################################################################\n",
    "    if session is None:\n",
    "        session = cach\n",
    "    if not url.startswith('http://') and not url.startswith('https://'):\n",
    "        url = base_url.format(url)\n",
    "    ###############################################################################################    \n",
    "    ###if the specified parameters are a dictionary, update params with the specified parameters###\n",
    "    ###############################################################################################\n",
    "    params = dict(base_params)\n",
    "    if params_provider:\n",
    "        if isinstance(params_provider, dict):\n",
    "            params.update(params_provider)\n",
    "        else:\n",
    "            params.update(params_provider())\n",
    "    ### in case you only scrape one page, it will just return the df of the respective page###\n",
    "    if not pagination_provider:\n",
    "        df, soup = return_data_frame(session, url, params, table_provider)\n",
    "        return df\n",
    "    ### in case you want to scrape multiple pages, create an empty list of dfs and add each df from each \n",
    "    ### page to the empty list, at the end you just concatenate all of the dfs\n",
    "    else:\n",
    "        data_frames = []\n",
    "        page_params = dict(params)\n",
    "        while True:\n",
    "            df, soup = return_data_frame(session, url, page_params, table_provider)\n",
    "            data_frames.append(df)\n",
    "            # Make sure columns retain their names\n",
    "            data_frames[-1].columns = data_frames[0].columns\n",
    "            new_params = pagination_provider(soup, page_params)\n",
    "            if not new_params:\n",
    "                break\n",
    "            else:\n",
    "                page_params.update(new_params)\n",
    "        return pd.concat(data_frames, sort=False, ignore_index=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Function to get the documents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This is a function to get the documents in the filing details page for each filing. See below for an example page.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "get_filing_documents = lambda url, summary = 'Document Format Files' : get_sec_table(url,\n",
    "                                                                                    table_provider = table_provider_by_summary(summary, index_col=None),\n",
    "                                                                                    pagination_provider = pagination_provider_by_element_start_count(('input',), {'value': 'Next 100'}))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Scraping most recent filings"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For the previous 5 days"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "base_url = 'https://www.sec.gov{}'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_current_events(days_before=0, form_type=''):\n",
    "    soup = BeautifulSoup(cach.get(base_url.format('/cgi-bin/current'), \n",
    "                            params={'q1': days_before, 'q2': 0, 'q3': form_type}).text)\n",
    "    pre = soup.find('pre')\n",
    "    ls = []\n",
    "    for line in str(pre).replace('<hr>', '\\n').replace('<hr/>', '\\n').split('\\n'):\n",
    "        bs_line = BeautifulSoup(line)\n",
    "        clean_line = '  '.join(item.strip() for item in bs_line.find_all(text=True))\n",
    "        split_line = [ x.strip() for x in clean_line.split('  ') if x.strip() ]\n",
    "        split_line += [ a.get('href') for a in bs_line.find_all('a') ]\n",
    "        if not all(x is None for x in split_line): ls.append(split_line)\n",
    "    colnames = ls[0] + [ 'link_{}'.format(i) for i in range(max(len(l) for l in ls) - len(ls[0])) ]\n",
    "    return pd.DataFrame(ls[1:], columns=colnames)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "get_current_events(form_type='8-K').head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Downloading SEC documents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Questions: \n",
    "* What is the purpose of defining a directory? It does not seem to work when I use it as a parameter for download_sec_documents\n",
    "\n",
    "* What does the error \"index 0 is out of bounds for axis 0 with size 0\" mean? I still manage to download the files."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "def download_sec_documents(doc_link):\n",
    "    contents = clean_sec_content(cach.get(base_url.format(doc_link)).content)\n",
    "    name = slugify(doc_link)\n",
    "    with open(name, 'w') as f: f.write(contents)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Downloading 424B5s"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "forms = get_current_events(0, '424B5')\n",
    "for link in forms['link_0']:\n",
    "    docs = get_filing_documents(base_url.format(link))\n",
    "    doc_link = docs.loc[docs.Type == '424B5', 'Document'].values[0]\n",
    "    download_sec_documents(doc_link)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Downloading 8-Ks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Scraping day-page: 0\n"
     ]
    },
    {
     "ename": "IndexError",
     "evalue": "index 0 is out of bounds for axis 0 with size 0",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mIndexError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-34-b32128899b65>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      6\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mlink\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mforms\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'link_0'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      7\u001b[0m         \u001b[0mdocs\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mget_filing_documents\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbase_url\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mformat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlink\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 8\u001b[0;31m         \u001b[0mdoc_link\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdocs\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloc\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mdocs\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mType\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'8-K'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'Document'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      9\u001b[0m         \u001b[0mdownload_sec_documents\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdoc_link\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mIndexError\u001b[0m: index 0 is out of bounds for axis 0 with size 0"
     ]
    }
   ],
   "source": [
    "num_days = 2\n",
    "\n",
    "for p in range(0, num_days):\n",
    "    print('Scraping day-page:', p)\n",
    "    forms = get_current_events(p, '8-K')\n",
    "    for link in forms['link_0']:\n",
    "        docs = get_filing_documents(base_url.format(link))\n",
    "        doc_link = docs.loc[docs.Type == '8-K', 'Document'].values[0]\n",
    "        download_sec_documents(doc_link)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "To download the 8-K I always get the index error above, however when I try to download 424B5 filings this is not a issue. This happens in the filing details page: \n",
    "\n",
    "8-K example: https://www.sec.gov/Archives/edgar/data/926660/0001193125-20-298746-index.html\n",
    "\n",
    "424B5 example: https://www.sec.gov/Archives/edgar/data/1035443/0001047469-19-001263-index.html\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Summary extraction"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "There is a difference between 424B5 and 8-K forms. The 424B5 forms have summary tables that are what the extract_dual_tables function extracts. We are interested in extracting the text from both forms, not necessarily the tables.\n",
    "\n",
    "File that I am going to be working with: https://www.sec.gov/Archives/edgar/data/1174940/000149315220022121/form424b5.htm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "def match_by_name_and_regex(name, regex, lowercase=True):\n",
    "    return lambda el: el.name == name and re.search(regex, el.text.lower() if lowercase else el.text) is not None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "# this function is going to give us all the headers that relate to risk factors in a filing\n",
    "def get_offering_header_candidates(soup):\n",
    "    return soup.find_all(match_by_name_and_regex('a', r'\\s*factors\\s*'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "content = read_html('-archives-edgar-data-1174940-000149315220022121-form424b5.htm')\n",
    "cleaned_content = clean_html(content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<a href=\"#v_005\">RISK\n",
       "     FACTORS</a>,\n",
       " <a href=\"#cj_001\">RISK FACTORS</a>,\n",
       " <a href=\"#cj_001\">RISK FACTORS</a>]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_offering_header_candidates(cleaned_content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Approach 1: \n",
    "Listing the titles in the document that correspond to risk factors (let's call them target_titles) --> get_offering_header_candidates\n",
    "\n",
    "Then we need to parse everything that is between the target_titles and the next title that does not match using match_by_name_and_regex('a', r'\\s*factors\\s*').\n",
    "\n",
    "We need to loop through each item, if the item is null or not a string, we need to skip them. If not, we are going to append them to an empty list. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "cleaned_content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<a href=\"#v_005\">RISK\n",
       "    FACTORS</a>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# In order to find the paragraph under the header:\n",
    "get_offering_header_candidates(cleaned_content)[0]\n",
    "\n",
    "# we need to first find the p tag that is parent to this a tag, and then loop through every sibling\n",
    "# of the parent tag and add it to an empty list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<td><a href=\"#v_001\">ABOUT\n",
      "    THIS PROSPECTUS SUPPLEMENT</a></td>\n",
      "<td><a href=\"#v_002\">CAUTIONARY\n",
      "    STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</a></td>\n",
      "<td><a href=\"#v_003\">PROSPECTUS\n",
      "    SUPPLEMENT SUMMARY</a></td>\n",
      "<td><a href=\"#v_004\">THE\n",
      "    OFFERING</a></td>\n",
      "<td><a href=\"#v_005\">RISK\n",
      "    FACTORS</a></td>\n",
      "<td><a href=\"#g_001\">CAPITALIZATION</a></td>\n",
      "<td><a href=\"#g_002\">USE\n",
      "    OF PROCEEDS</a></td>\n",
      "<td><a href=\"#g_003\">DIVIDEND\n",
      "    POLICY</a></td>\n",
      "<td><a href=\"#g_004\">DILUTION</a></td>\n",
      "<td><a href=\"#g_005\">UNDERWRITING</a></td>\n",
      "<td><a href=\"#g_006\">LEGAL\n",
      "    MATTERS</a></td>\n",
      "<td><a href=\"#g_007\">EXPERTS</a></td>\n",
      "<td><a href=\"#g_008\">WHERE\n",
      "    YOU CAN FIND MORE INFORMATION</a></td>\n",
      "<td><a href=\"#g_009\">INFORMATION\n",
      "    INCORPORATED BY REFERENCE</a></td>\n",
      "<td><a href=\"#g_010\">ABOUT\n",
      "    THIS PROSPECTUS</a></td>\n",
      "<td><a href=\"#g_011\">PROSPECTUS\n",
      "    SUMMARY</a></td>\n",
      "<td><a href=\"#g_012\">SECURITIES\n",
      "    WE MAY OFFER</a></td>\n",
      "<td><a href=\"#cj_001\">RISK FACTORS</a></td>\n",
      "<td><a href=\"#cj_002\">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></td>\n",
      "<td><a href=\"#cj_003\">USE OF PROCEEDS</a></td>\n",
      "<td><a href=\"#cj_004\">DIVIDEND POLICY</a></td>\n",
      "<td><a href=\"#cj_005\">DESCRIPTION OF CAPITAL STOCK</a></td>\n",
      "<td><a href=\"#cj_006\">DESCRIPTION OF WARRANTS</a></td>\n",
      "<td><a href=\"#cj_007\">DESCRIPTION OF UNITS</a></td>\n",
      "<td><a href=\"#cj_008\">LEGAL OWNERSHIP OF SECURITIES</a></td>\n",
      "<td><a href=\"#cj_009\">PLAN OF DISTRIBUTION</a></td>\n",
      "<td><a href=\"#cj_010\">LEGAL MATTERS</a></td>\n",
      "<td><a href=\"#cj_011\">EXPERTS</a></td>\n",
      "<td><a href=\"#cj_012\">WHERE YOU CAN FIND MORE INFORMATION</a></td>\n",
      "<td><a href=\"#cj_013\">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></td>\n",
      "<p><a name=\"v_001\"></a>ABOUT\n",
      "THIS PROSPECTUS SUPPLEMENT</p>\n",
      "<p><a name=\"v_002\"></a>CAUTIONARY\n",
      "STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</p>\n",
      "<p><a name=\"v_003\"></a>PROSPECTUS\n",
      "SUPPLEMENT SUMMARY</p>\n",
      "<p><a name=\"v_004\"></a>THE\n",
      "OFFERING</p>\n",
      "<p><a name=\"v_005\"></a>RISK\n",
      "FACTORS</p>\n",
      "<p><a name=\"g_001\"></a>CAPITALIZATION</p>\n",
      "<p><a name=\"g_002\"></a>USE\n",
      "OF PROCEEDS</p>\n",
      "<p><a name=\"g_003\"></a>DIVIDEND\n",
      "POLICY</p>\n",
      "<p><a name=\"g_004\"></a>DILUTION</p>\n",
      "<p><a name=\"g_005\"></a>UNDERWRITING</p>\n",
      "<p><a name=\"g_006\"></a>LEGAL\n",
      "MATTERS</p>\n",
      "<p><a name=\"g_007\"></a>EXPERTS</p>\n",
      "<p><a name=\"g_008\"></a>WHERE\n",
      "YOU CAN FIND MORE INFORMATION</p>\n",
      "<p><a name=\"g_009\"></a>INFORMATION\n",
      "INCORPORATED BY REFERENCE</p>\n",
      "<td><a href=\"#g_010\">ABOUT\n",
      "    THIS PROSPECTUS</a></td>\n",
      "<td><a href=\"#g_011\">PROSPECTUS\n",
      "    SUMMARY</a></td>\n",
      "<td><a href=\"#g_012\">SECURITIES\n",
      "    WE MAY OFFER</a></td>\n",
      "<td><a href=\"#cj_001\">RISK FACTORS</a></td>\n",
      "<td><a href=\"#cj_002\">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></td>\n",
      "<td><a href=\"#cj_003\">USE OF PROCEEDS</a></td>\n",
      "<td><a href=\"#cj_004\">DIVIDEND POLICY</a></td>\n",
      "<td><a href=\"#cj_005\">DESCRIPTION OF CAPITAL STOCK</a></td>\n",
      "<td><a href=\"#cj_006\">DESCRIPTION OF WARRANTS</a></td>\n",
      "<td><a href=\"#cj_007\">DESCRIPTION OF UNITS</a></td>\n",
      "<td><a href=\"#cj_008\">LEGAL OWNERSHIP OF SECURITIES</a></td>\n",
      "<td><a href=\"#cj_009\">PLAN OF DISTRIBUTION</a></td>\n",
      "<td><a href=\"#cj_010\">LEGAL MATTERS</a></td>\n",
      "<td><a href=\"#cj_011\">EXPERTS</a></td>\n",
      "<td><a href=\"#cj_012\">WHERE YOU CAN FIND MORE INFORMATION</a></td>\n",
      "<td><a href=\"#cj_013\">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></td>\n",
      "<p><a name=\"g_010\"></a><strong>ABOUT\n",
      "THIS PROSPECTUS</strong></p>\n",
      "<p><a name=\"g_011\"></a><strong>PROSPECTUS\n",
      "SUMMARY</strong></p>\n",
      "<p><a name=\"g_012\"></a><strong>SECURITIES\n",
      "WE MAY OFFER</strong></p>\n",
      "<strong><a name=\"cj_001\"></a>RISK\n",
      "FACTORS</strong>\n",
      "<p><a name=\"cj_002\"></a><strong>SPECIAL\n",
      "NOTE REGARDING FORWARD-LOOKING STATEMENTS</strong></p>\n",
      "<strong><a name=\"cj_003\"></a>USE\n",
      "OF PROCEEDS</strong>\n",
      "<p><a name=\"cj_004\"></a><strong>DIVIDEND\n",
      "POLICY</strong></p>\n",
      "<strong><a name=\"cj_005\"></a>DESCRIPTION\n",
      "OF CAPITAL STOCK</strong>\n",
      "<p><a name=\"cj_006\"></a><strong>DESCRIPTION\n",
      "OF WARRANTS</strong></p>\n",
      "<p><a name=\"cj_007\"></a><strong>DESCRIPTION\n",
      "OF UNITS</strong></p>\n",
      "<strong><a name=\"cj_008\"></a>LEGAL\n",
      "OWNERSHIP OF SECURITIES</strong>\n",
      "<p><a name=\"cj_009\"></a><strong>PLAN\n",
      "OF DISTRIBUTION</strong></p>\n",
      "<strong><a name=\"cj_010\"></a>LEGAL\n",
      "MATTERS</strong>\n",
      "<p><a name=\"cj_011\"></a><strong>EXPERTS</strong></p>\n",
      "<p><a name=\"cj_012\"></a><strong>WHERE\n",
      "YOU CAN FIND ADDITIONAL INFORMATION</strong></p>\n",
      "<strong><a name=\"cj_013\"></a>INCORPORATION\n",
      "OF CERTAIN DOCUMENTS BY REFERENCE</strong>\n"
     ]
    }
   ],
   "source": [
    "for tag in cleaned_content.find_all('a'):\n",
    "    parent = tag.parent\n",
    "    if parent is not None:\n",
    "        print(parent)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "##This is the tag we are interested in \n",
    "<p><a name=\"v_005\"></a>RISK FACTORS</p>\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<p>This\n",
      "prospectus supplement and the accompanying prospectus form part of a registration statement on Form S-3 that we filed with the\n",
      "Securities and Exchange Commission, or the “SEC,” using a “shelf” registration process. This document\n",
      "contains two parts. The first part consists of this prospectus supplement, which provides you with specific information about\n",
      "this offering. The second part, the accompanying prospectus, provides more general information, some of which may not apply to\n",
      "this offering. Generally, when we refer only to the “prospectus,” we are referring to both parts combined. This prospectus\n",
      "supplement, and the information incorporated herein by reference, may add, update or change information in the accompanying prospectus.\n",
      "You should read the entire prospectus supplement as well as the accompanying prospectus and the documents incorporated by reference\n",
      "herein that are described under the headings “Where You Can Find More Information” and “Incorporation of Certain\n",
      "Documents by Reference.” If there is any inconsistency between the information in this prospectus supplement and the accompanying\n",
      "prospectus, you should rely on the information in this prospectus supplement.</p>\n",
      "<p>Certain\n",
      "statements in this prospectus supplement, the accompanying prospectus and documents incorporated by reference herein that look\n",
      "forward in time or express management’s expectations or beliefs with respect to the occurrence of future events are forward-looking\n",
      "statements as defined under within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and\n",
      "Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act, as amended, and are subject to the safe harbor\n",
      "created therein for forward-looking statements. Such statements include, but are not limited to, (i) projections of revenue, earnings,\n",
      "capital structure and other financial items, (ii) statements of our plans and objectives, (iii) statements of expected future\n",
      "economic performance, and (iv) assumptions underlying statements regarding us or our business. Forward-looking statements can\n",
      "be identified by, among other things, the use of forward-looking language, such as “believes,” “expects,”\n",
      "“estimates,” “may,” “will,” “should,” “could,” “seeks,”\n",
      "“plans,” “intends,” “anticipates” or “scheduled to” or the negatives of those\n",
      "terms, or other variations of those terms or comparable language, including, notably, language concerning the “impact”\n",
      "or “limitations” relating to COVID-19, or by discussions of strategy or other intentions, particularly as they relate\n",
      "to the development and funding of our new TerraCoV2 vaccine product candidate.</p>\n",
      "<p><i>This\n",
      "summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the\n",
      "accompanying prospectus. This summary may not contain all of the information that may be important to you. You should read this\n",
      "prospectus supplement, the accompanying prospectus, the information incorporated by reference in each, and any related free writing\n",
      "prospectus before making an investment decision. You should pay special attention to the “Risk Factors” section beginning\n",
      "on page S-9 of this prospectus supplement and “Risk Factors” set forth in our most recent annual report on Form 10-K\n",
      "for the year ended December 31, 2019, as updated by our recent Form 8-K Report filed with the Securities and Exchange Commission\n",
      "on May 8, 2020 and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30,\n",
      "2020, respectively and in the other documents which are incorporated by reference in this prospectus supplement and the accompanying\n",
      "prospectus in their entirety to determine whether an investment in our common stock is appropriate for you.</i></p>\n",
      "<p><i>The\n",
      "following summary contains basic information about our Common Stock and the offering and is not intended to be complete. It does\n",
      "not contain all the information that may be important to you. For a more complete understanding of our Common Stock, you should\n",
      "read the section of the accompanying prospectus entitled “Description of Capital Stock.”</i></p>\n",
      "<p><i>Before\n",
      "purchasing our common stock you should carefully consider the risk factors set forth below and under the heading “Risk Factors”\n",
      "included in our most recent Annual Report on Form 10-K, as updated by our recent Form 8-K Report filed with the Securities and\n",
      "Exchange Commission on May 8, 2020, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, each of which\n",
      "are on file with the SEC and are incorporated herein by reference, as well as all other information contained in this prospectus\n",
      "supplement and the accompanying prospectus and incorporated by reference and any free writing prospectus that we have authorized\n",
      "for use in connection with this offering. The risks and uncertainties described below and in our most recent Annual Report on\n",
      "Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, are not the only risks and uncertainties\n",
      "we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our\n",
      "business operations. If any of the risks described below or in our most recent Annual Report on Form 10-K, as revised or supplemented\n",
      "by our subsequent Quarterly Reports on Form 10-Q, actually occur, our business, financial condition and results of operations\n",
      "could suffer. As a result, the trading price of our stock could decline, perhaps significantly, and you could lose all or part\n",
      "of your investment. The risks discussed below and in most recent Annual Report on Form 10-K, as revised or supplemented by our\n",
      "subsequent Quarterly Reports on Form 10-Q, also include forward-looking statements and our actual results may differ substantially\n",
      "from those discussed in these forward-looking statements. See the section entitled “Forward-Looking Information.”</i></p>\n",
      "<p>The\n",
      "following table sets forth our cash and capitalization as of September 30, 2020:</p>\n",
      "<p>We\n",
      "estimate that the net proceeds from this offering will be approximately $4,673,700 after deducting our estimated offering\n",
      "expenses payable by us.</p>\n",
      "<p>To\n",
      "date, we have neither declared nor paid any dividends on our common stock nor do we anticipate that such dividends will be paid\n",
      "in the foreseeable future. Rather, we intend to retain any earnings to finance the growth and development of our business. Any\n",
      "payment of cash dividends on our common stock in the future will be dependent, among other things, upon our earnings, financial\n",
      "condition, capital requirements and other factors which the board of directors deems relevant. In addition, restrictive covenants\n",
      "contained in any financing agreements entered into in the future may preclude us from paying any dividends.</p>\n",
      "<p>If\n",
      "you invest in our securities, your interest will be diluted to the extent of the difference between the public offering price\n",
      "per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering.</p>\n",
      "<p>Under\n",
      "the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus supplement, the underwriter\n",
      "named below has agreed to purchase, and we have agreed to sell to the underwriter, the number of shares of common stock indicated\n",
      "below.</p>\n",
      "<p>The\n",
      "validity of the issuance of the securities offered hereby will be passed upon for us by Shumaker, Loop &amp; Kendrick, LLP. Certain\n",
      "legal matters in connection with the offering will be passed upon for the underwriter by McDermott Will &amp; Emery LLP.</p>\n",
      "<p>The\n",
      "financial statements incorporated in this prospectus by reference from the Company’s Annual Report on Form 10-K have been\n",
      "audited by Mayer Hoffman McCann P.C., an independent registered public accounting firm, as stated in their report (which report\n",
      "includes an explanatory paragraph relating to the Company’s ability to continue as a going concern), which is incorporated\n",
      "herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their\n",
      "authority as experts in accounting and auditing Mayer Hoffman McCann P.C. has no interest in the shares being registered in this\n",
      "filing.</p>\n",
      "<p>We\n",
      "are a public company and file annual, quarterly and current reports, proxy statements and other information with the Securities\n",
      "and Exchange Commission (“SEC”).You can request copies of these documents by writing to the SEC and paying a fee for\n",
      "the copying cost. Our SEC filings are also available to the public at the SEC’s web site at http://www.sec.gov.</p>\n",
      "<p>In\n",
      "this document, we “incorporate by reference” certain information we file with the SEC, which means that we can disclose\n",
      "important information to you by referring to that information. The information incorporated by reference is considered to be a\n",
      "part of this prospectus supplement. Any statement contained in a document incorporated by reference herein shall be deemed to\n",
      "be modified or superseded for all purposes to the extent that a statement contained in this prospectus supplement or in any other\n",
      "subsequently filed document that is also incorporated or deemed to be incorporated by reference, modifies or supersedes such statement.\n",
      "Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this\n",
      "prospectus supplement. We incorporate by reference the documents listed below (other than, in each case, documents or information\n",
      "deemed to be furnished and not filed in accordance with SEC rules):</p>\n",
      "<p>This\n",
      "prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC,\n",
      "utilizing a “shelf” registration process. Under this shelf registration statement, we may, from time to time, sell\n",
      "any combination of the securities referred to herein in one or more offerings for total gross proceeds of up to $50,000,000. This\n",
      "prospectus provides you with a general description of the securities we may offer.</p>\n",
      "<p><i>The\n",
      "items in the following summary are described in more detail elsewhere in this prospectus and in the documents incorporated by\n",
      "reference herein. This summary provides an overview of selected information and does not contain all the information you should\n",
      "consider before investing in our common stock. Therefore, you should read the entire prospectus and any free writing prospectus\n",
      "that we have authorized for use in connection with this offering carefully, including the “Risk Factors” section and\n",
      "other documents or information included or incorporated by reference in this prospectus before making any investment decision.</i></p>\n",
      "<p>We\n",
      "may offer shares of our common stock, warrant shares of our common stock to purchase, either individually or in combination, and/or\n",
      "units consisting of some or all of such securities for total gross proceeds of up to $50.0 million, from time to time under this\n",
      "prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms\n",
      "to be determined by market conditions at the time of any offering. This prospectus provides you with a general description of\n",
      "the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus\n",
      "supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including\n",
      "to the extent applicable:</p>\n",
      "<p>This\n",
      "prospectus and the documents incorporated by reference herein contain forward-looking statements. These are based on our management’s\n",
      "current beliefs, expectations and assumptions about future events, conditions and results and on information currently available\n",
      "to us. Discussions containing these forward-looking statements may be found, among other places, in the sections entitled “Business,”\n",
      "“Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”\n",
      "contained in the documents incorporated by reference herein.</p>\n",
      "<p>We\n",
      "have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common\n",
      "stock for the foreseeable future. We intend to use all available cash and liquid assets in the operation and growth of our business.\n",
      "Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend\n",
      "upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as our board of\n",
      "directors deems relevant.</p>\n",
      "<p>The\n",
      "following description, together with the additional information that we include in any applicable prospectus supplement and in\n",
      "any related free writing prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions\n",
      "of the warrants that we may offer under this prospectus, which may be issued in one or more series. Warrants may be offered independently\n",
      "or in combination with other securities offered by any prospectus supplement. While the terms we have summarized below will apply\n",
      "generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants\n",
      "in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered\n",
      "by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for\n",
      "a particular series of warrants may specify different or additional terms.</p>\n",
      "<p><strong><i>Units</i></strong></p>\n",
      "<p>We\n",
      "may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public,\n",
      "negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus\n",
      "may also be effected through the issuance of derivative securities, including without limitation, warrants and subscriptions.\n",
      "We may sell the securities to or through underwriters or dealers, through one or more agents, or directly to one or more purchasers.\n",
      "We may distribute securities from time to time in one or more transactions:</p>\n",
      "<p>The\n",
      "audited financial statements of Oragenics, Inc. as of December 31, 2018 and 2017, and for the two-year period ended December 31,\n",
      "2018, included in our Annual Report on Form 10-K for the year ended December 31, 2018, incorporated by reference in this prospectus\n",
      "have been audited by Mayer Hoffman McCann P.C., an independent registered public accounting firm, as stated in their report dated\n",
      "March 29, 2019, which is incorporated by reference herein, and has been so incorporated in reliance upon the report of such firm\n",
      "given upon their authority as experts in accounting and auditing.</p>\n",
      "<p>This\n",
      "prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information\n",
      "set forth in the registration statement and the exhibits to the registration statement. For further information with respect to\n",
      "us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules\n",
      "filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated\n",
      "by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making\n",
      "an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this\n",
      "prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery\n",
      "of this prospectus or any sale of the securities offered by this prospectus.</p>\n"
     ]
    }
   ],
   "source": [
    "# here I am trying to find the paragraphs in the section of RISK FACTORS\n",
    "for tag in cleaned_content.find_all('a'):\n",
    "    parent = tag.parent\n",
    "    if parent is not None and parent.name == 'p':\n",
    "        uncle = parent.next_sibling\n",
    "        if str(uncle).strip() == '':\n",
    "            uncle = uncle.next_sibling\n",
    "            if uncle is not None: \n",
    "                print(uncle)\n",
    "## this code works for only one paragraph after the header title, we should loop through every \n",
    "# p tag after the header"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_risk_info(header):\n",
    "    paragraphs = ''\n",
    "    parent = header.parent\n",
    "    while True:\n",
    "        if parent is None: break # here you loop through each element until there exists a parent\n",
    "        if parent.name != 'p': # if the parent of an a tag is not a p, it will loop through\n",
    "            break              # each item until there is one that is a p tag. If it is, we get the uncle\n",
    "        else:\n",
    "            uncle = parent.next_sibling\n",
    "            continue\n",
    "        if uncle is None: break\n",
    "        if str(uncle).strip() == '': ## in between two p tags, there is a p tag that doesn't contain anything\n",
    "            uncle = uncle.next_sibling # so if we land in a tag without any text, we just need to get the sibling of that tag\n",
    "            paragraphs += str(uncle)\n",
    "    return paragraphs\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_paragraphs(soup):\n",
    "    for header in get_offering_header_candidates(soup):\n",
    "        paragraphs = get_risk_info(header)\n",
    "        if paragraphs:\n",
    "            return paragraphs\n",
    "        else:\n",
    "            print('try again')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "try again\n",
      "try again\n",
      "try again\n"
     ]
    }
   ],
   "source": [
    "extract_paragraphs(cleaned_content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Approach 2: \n",
    "\n",
    "We can get the sourceline and source position of each title in a document by using an html parser. Then we identify the target_titles, their coordinates, and store the coordinates of target_titles and target_titles + 1 in a dataframe.\n",
    "\n",
    "After creating the dataframe, we can parse everything with coordinates in between target_titles and target_titles + 1."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<a href=\"#v_001\"><font style=\"font-size: 10pt\">ABOUT\n",
       "     THIS PROSPECTUS SUPPLEMENT</font></a>,\n",
       " <a href=\"#v_002\"><font style=\"font-size: 10pt\">CAUTIONARY\n",
       "     STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</font></a>,\n",
       " <a href=\"#v_003\"><font style=\"font-size: 10pt\">PROSPECTUS\n",
       "     SUPPLEMENT SUMMARY</font></a>,\n",
       " <a href=\"#v_004\"><font style=\"font-size: 10pt\">THE\n",
       "     OFFERING</font></a>,\n",
       " <a href=\"#v_005\"><font style=\"font-size: 10pt\">RISK\n",
       "     FACTORS</font></a>,\n",
       " <a href=\"#g_001\"><font style=\"font-size: 10pt\">CAPITALIZATION</font></a>,\n",
       " <a href=\"#g_002\"><font style=\"font-size: 10pt\">USE\n",
       "     OF PROCEEDS</font></a>,\n",
       " <a href=\"#g_003\"><font style=\"font-size: 10pt\">DIVIDEND\n",
       "     POLICY</font></a>,\n",
       " <a href=\"#g_004\"><font style=\"font-size: 10pt\">DILUTION</font></a>,\n",
       " <a href=\"#g_005\"><font style=\"font-size: 10pt\">UNDERWRITING</font></a>,\n",
       " <a href=\"#g_006\"><font style=\"font-size: 10pt\">LEGAL\n",
       "     MATTERS</font></a>,\n",
       " <a href=\"#g_007\"><font style=\"font-size: 10pt\">EXPERTS</font></a>,\n",
       " <a href=\"#g_008\"><font style=\"font-size: 10pt\">WHERE\n",
       "     YOU CAN FIND MORE INFORMATION</font></a>,\n",
       " <a href=\"#g_009\"><font style=\"font-size: 10pt\">INFORMATION\n",
       "     INCORPORATED BY REFERENCE</font></a>,\n",
       " <a href=\"#g_010\"><font style=\"font-size: 10pt\">ABOUT\n",
       "     THIS PROSPECTUS</font></a>,\n",
       " <a href=\"#g_011\"><font style=\"font-size: 10pt\">PROSPECTUS\n",
       "     SUMMARY</font></a>,\n",
       " <a href=\"#g_012\"><font style=\"font-size: 10pt\">SECURITIES\n",
       "     WE MAY OFFER</font></a>,\n",
       " <a href=\"#cj_001\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">RISK FACTORS</font></a>,\n",
       " <a href=\"#cj_002\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a>,\n",
       " <a href=\"#cj_003\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">USE OF PROCEEDS</font></a>,\n",
       " <a href=\"#cj_004\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">DIVIDEND POLICY</font></a>,\n",
       " <a href=\"#cj_005\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">DESCRIPTION OF CAPITAL STOCK</font></a>,\n",
       " <a href=\"#cj_006\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">DESCRIPTION OF WARRANTS</font></a>,\n",
       " <a href=\"#cj_007\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">DESCRIPTION OF UNITS</font></a>,\n",
       " <a href=\"#cj_008\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">LEGAL OWNERSHIP OF SECURITIES</font></a>,\n",
       " <a href=\"#cj_009\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">PLAN OF DISTRIBUTION</font></a>,\n",
       " <a href=\"#cj_010\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">LEGAL MATTERS</font></a>,\n",
       " <a href=\"#cj_011\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">EXPERTS</font></a>,\n",
       " <a href=\"#cj_012\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">WHERE YOU CAN FIND MORE INFORMATION</font></a>,\n",
       " <a href=\"#cj_013\"><font style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a>,\n",
       " <a name=\"v_001\"></a>,\n",
       " <a name=\"v_002\"></a>,\n",
       " <a name=\"v_003\"></a>,\n",
       " <a name=\"v_004\"></a>,\n",
       " <a name=\"v_005\"></a>,\n",
       " <a name=\"g_001\"></a>,\n",
       " <a name=\"g_002\"></a>,\n",
       " <a name=\"g_003\"></a>,\n",
       " <a name=\"g_004\"></a>,\n",
       " <a name=\"g_005\"></a>,\n",
       " <a name=\"g_006\"></a>,\n",
       " <a name=\"g_007\"></a>,\n",
       " <a name=\"g_008\"></a>,\n",
       " <a name=\"g_009\"></a>,\n",
       " <a href=\"#g_010\">ABOUT\n",
       "     THIS PROSPECTUS</a>,\n",
       " <a href=\"#g_011\">PROSPECTUS\n",
       "     SUMMARY</a>,\n",
       " <a href=\"#g_012\">SECURITIES\n",
       "     WE MAY OFFER</a>,\n",
       " <a href=\"#cj_001\"><font style=\"font-family: Times New Roman, Times, Serif\">RISK FACTORS</font></a>,\n",
       " <a href=\"#cj_002\"><font style=\"font-family: Times New Roman, Times, Serif\">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a>,\n",
       " <a href=\"#cj_003\"><font style=\"font-family: Times New Roman, Times, Serif\">USE OF PROCEEDS</font></a>,\n",
       " <a href=\"#cj_004\"><font style=\"font-family: Times New Roman, Times, Serif\">DIVIDEND POLICY</font></a>,\n",
       " <a href=\"#cj_005\"><font style=\"font-family: Times New Roman, Times, Serif\">DESCRIPTION OF CAPITAL STOCK</font></a>,\n",
       " <a href=\"#cj_006\"><font style=\"font-family: Times New Roman, Times, Serif\">DESCRIPTION OF WARRANTS</font></a>,\n",
       " <a href=\"#cj_007\"><font style=\"font-family: Times New Roman, Times, Serif\">DESCRIPTION OF UNITS</font></a>,\n",
       " <a href=\"#cj_008\"><font style=\"font-family: Times New Roman, Times, Serif\">LEGAL OWNERSHIP OF SECURITIES</font></a>,\n",
       " <a href=\"#cj_009\"><font style=\"font-family: Times New Roman, Times, Serif\">PLAN OF DISTRIBUTION</font></a>,\n",
       " <a href=\"#cj_010\"><font style=\"font-family: Times New Roman, Times, Serif\">LEGAL MATTERS</font></a>,\n",
       " <a href=\"#cj_011\"><font style=\"font-family: Times New Roman, Times, Serif\">EXPERTS</font></a>,\n",
       " <a href=\"#cj_012\"><font style=\"font-family: Times New Roman, Times, Serif\">WHERE YOU CAN FIND MORE INFORMATION</font></a>,\n",
       " <a href=\"#cj_013\"><font style=\"font-family: Times New Roman, Times, Serif\">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a>,\n",
       " <a name=\"g_010\"></a>,\n",
       " <a name=\"g_011\"></a>,\n",
       " <a name=\"g_012\"></a>,\n",
       " <a name=\"cj_001\"></a>,\n",
       " <a name=\"cj_002\"></a>,\n",
       " <a name=\"cj_003\"></a>,\n",
       " <a name=\"cj_004\"></a>,\n",
       " <a name=\"cj_005\"></a>,\n",
       " <a name=\"cj_006\"></a>,\n",
       " <a name=\"cj_007\"></a>,\n",
       " <a name=\"cj_008\"></a>,\n",
       " <a name=\"cj_009\"></a>,\n",
       " <a name=\"cj_010\"></a>,\n",
       " <a name=\"cj_011\"></a>,\n",
       " <a name=\"cj_012\"></a>,\n",
       " <a name=\"cj_013\"></a>]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup = BeautifulSoup(content, 'html.parser')\n",
    "soup.find_all('a')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(157, 114, 'ABOUT\\n    THIS PROSPECTUS SUPPLEMENT'),\n",
       " (161, 114, 'CAUTIONARY\\n    STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS'),\n",
       " (165, 114, 'PROSPECTUS\\n    SUPPLEMENT SUMMARY'),\n",
       " (169, 114, 'THE\\n    OFFERING'),\n",
       " (173, 114, 'RISK\\n    FACTORS'),\n",
       " (177, 114, 'CAPITALIZATION'),\n",
       " (180, 114, 'USE\\n    OF PROCEEDS'),\n",
       " (184, 114, 'DIVIDEND\\n    POLICY'),\n",
       " (188, 114, 'DILUTION'),\n",
       " (191, 114, 'UNDERWRITING'),\n",
       " (194, 114, 'LEGAL\\n    MATTERS'),\n",
       " (198, 114, 'EXPERTS'),\n",
       " (201, 114, 'WHERE\\n    YOU CAN FIND MORE INFORMATION'),\n",
       " (205, 114, 'INFORMATION\\n    INCORPORATED BY REFERENCE'),\n",
       " (219, 114, 'ABOUT\\n    THIS PROSPECTUS'),\n",
       " (223, 114, 'PROSPECTUS\\n    SUMMARY'),\n",
       " (227, 114, 'SECURITIES\\n    WE MAY OFFER'),\n",
       " (231, 57, 'RISK FACTORS'),\n",
       " (234, 57, 'SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS'),\n",
       " (237, 57, 'USE OF PROCEEDS'),\n",
       " (240, 57, 'DIVIDEND POLICY'),\n",
       " (243, 57, 'DESCRIPTION OF CAPITAL STOCK'),\n",
       " (246, 57, 'DESCRIPTION OF WARRANTS'),\n",
       " (249, 57, 'DESCRIPTION OF UNITS'),\n",
       " (252, 57, 'LEGAL OWNERSHIP OF SECURITIES'),\n",
       " (255, 57, 'PLAN OF DISTRIBUTION'),\n",
       " (258, 57, 'LEGAL MATTERS'),\n",
       " (261, 57, 'EXPERTS'),\n",
       " (264, 57, 'WHERE YOU CAN FIND MORE INFORMATION'),\n",
       " (267, 57, 'INCORPORATION OF CERTAIN INFORMATION BY REFERENCE'),\n",
       " (279, 184, None),\n",
       " (366, 167, None),\n",
       " (732, 184, None),\n",
       " (1058, 162, None),\n",
       " (1251, 184, None),\n",
       " (1857, 167, None),\n",
       " (2038, 145, None),\n",
       " (2060, 145, None),\n",
       " (2095, 145, None),\n",
       " (2227, 201, None),\n",
       " (2445, 145, None),\n",
       " (2456, 145, None),\n",
       " (2470, 145, None),\n",
       " (2512, 167, None),\n",
       " (2705, 132, 'ABOUT\\n    THIS PROSPECTUS'),\n",
       " (2709, 132, 'PROSPECTUS\\n    SUMMARY'),\n",
       " (2713, 132, 'SECURITIES\\n    WE MAY OFFER'),\n",
       " (2717, 75, 'RISK FACTORS'),\n",
       " (2720, 75, 'SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS'),\n",
       " (2723, 57, 'USE OF PROCEEDS'),\n",
       " (2726, 75, 'DIVIDEND POLICY'),\n",
       " (2729, 75, 'DESCRIPTION OF CAPITAL STOCK'),\n",
       " (2732, 57, 'DESCRIPTION OF WARRANTS'),\n",
       " (2735, 57, 'DESCRIPTION OF UNITS'),\n",
       " (2738, 75, 'LEGAL OWNERSHIP OF SECURITIES'),\n",
       " (2741, 57, 'PLAN OF DISTRIBUTION'),\n",
       " (2744, 75, 'LEGAL MATTERS'),\n",
       " (2747, 57, 'EXPERTS'),\n",
       " (2750, 75, 'WHERE YOU CAN FIND MORE INFORMATION'),\n",
       " (2753, 75, 'INCORPORATION OF CERTAIN INFORMATION BY REFERENCE'),\n",
       " (2767, 162, None),\n",
       " (2855, 140, None),\n",
       " (3162, 140, None),\n",
       " (3329, 160, None),\n",
       " (3355, 105, None),\n",
       " (3522, 182, None),\n",
       " (3540, 157, None),\n",
       " (3570, 182, None),\n",
       " (4481, 83, None),\n",
       " (4738, 179, None),\n",
       " (4829, 182, None),\n",
       " (5155, 179, None),\n",
       " (5439, 182, None),\n",
       " (5451, 157, None),\n",
       " (5464, 157, None),\n",
       " (5502, 182, None)]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "positions = []\n",
    "for tag in soup.find_all('a'):\n",
    "    positions.append((tag.sourceline, tag.sourcepos,tag.string))\n",
    "positions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now I just have to store the coordinates and names of the target_titles and target_titles+1 in a dataframe."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "limit= len(positions)\n",
    "pattern = re.compile(r'\\s*')\n",
    "listing = []\n",
    "\n",
    "for i in range(0, limit-1):\n",
    "    if positions[i][2] is not None:\n",
    "        target = positions[i][2].replace('\\n', '')\n",
    "        target = re.sub(pattern, ' ', target)\n",
    "        if target == 'RISK FACTORS':\n",
    "            listing.append(positions[i])\n",
    "            listing.append(positions[i+1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(173, 114, 'RISK\\n    FACTORS'),\n",
       " (177, 114, 'CAPITALIZATION'),\n",
       " (231, 57, 'RISK FACTORS'),\n",
       " (234, 57, 'SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS'),\n",
       " (2717, 75, 'RISK FACTORS'),\n",
       " (2720, 75, 'SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS')]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "listing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>source-line</th>\n",
       "      <th>source-position</th>\n",
       "      <th>tag</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>173</td>\n",
       "      <td>114</td>\n",
       "      <td>RISK\\n    FACTORS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>177</td>\n",
       "      <td>114</td>\n",
       "      <td>CAPITALIZATION</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>231</td>\n",
       "      <td>57</td>\n",
       "      <td>RISK FACTORS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>234</td>\n",
       "      <td>57</td>\n",
       "      <td>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2717</td>\n",
       "      <td>75</td>\n",
       "      <td>RISK FACTORS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2720</td>\n",
       "      <td>75</td>\n",
       "      <td>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   source-line  source-position  \\\n",
       "0          173              114   \n",
       "1          177              114   \n",
       "2          231               57   \n",
       "3          234               57   \n",
       "4         2717               75   \n",
       "5         2720               75   \n",
       "\n",
       "                                                 tag  \n",
       "0                                  RISK\\n    FACTORS  \n",
       "1                                     CAPITALIZATION  \n",
       "2                                       RISK FACTORS  \n",
       "3  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS  \n",
       "4                                       RISK FACTORS  \n",
       "5  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.DataFrame(listing)\n",
    "df.columns = ['source-line', 'source-position', 'tag']\n",
    "df"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now that we have the coordinates that delimit the content we are interested in, we can set up a function that parses everything that is in between."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "702 31 Risk Factors\n",
      "735 179  \n",
      "737 158 This\n",
      "summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the\n",
      "accompanying prospectus. This summary may not contain all of the information that may be important to you. You should read this\n",
      "prospectus supplement, the accompanying prospectus, the information incorporated by reference in each, and any related free writing\n",
      "prospectus before making an investment decision. You should pay special attention to the “Risk Factors” section beginning\n",
      "on page S-9 of this prospectus supplement and “Risk Factors” set forth in our most recent annual report on Form 10-K\n",
      "for the year ended December 31, 2019, as updated by our recent Form 8-K Report filed with the Securities and Exchange Commission\n",
      "on May 8, 2020 and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30,\n",
      "2020, respectively and in the other documents which are incorporated by reference in this prospectus supplement and the accompanying\n",
      "prospectus in their entirety to determine whether an investment in our common stock is appropriate for you.\n",
      "760 158 Our\n",
      "SARS-CoV-2 Vaccine Product Candidate\n",
      "839 158 Our\n",
      "Antibiotic Product Candidate-OG716\n",
      "845 66 None\n",
      "889 0 Clostridium difficile (“C. diff”)\n",
      "914 92 C. diff\n",
      "915 121 C.\n",
      "diff\n",
      "916 125 C.\n",
      "diff\n",
      "918 6 C. diff\n",
      "933 158 Product\n",
      "Candidates\n",
      "957 161 Feedback\n",
      "From U.S. Food and Drug Administration (“FDA”).\n",
      "966 161 Funding\n",
      "Update From Biomedical Advanced Research and Development Authority (“BARDA”).\n",
      "974 161 Warrant\n",
      "Exercises. \n",
      "983 161 Additional\n",
      "Consideration Payment - NTI Acquisition\n",
      "984 47 .\n",
      "992 161  \n",
      "1063 158 The\n",
      "following summary contains basic information about our Common Stock and the offering and is not intended to be complete. It does\n",
      "not contain all the information that may be important to you. For a more complete understanding of our Common Stock, you should\n",
      "read the section of the accompanying prospectus entitled “Description of Capital Stock.”\n",
      "1254 179  \n",
      "1256 158 Before\n",
      "purchasing our common stock you should carefully consider the risk factors set forth below and under the heading “Risk Factors”\n",
      "included in our most recent Annual Report on Form 10-K, as updated by our recent Form 8-K Report filed with the Securities and\n",
      "Exchange Commission on May 8, 2020, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, each of which\n",
      "are on file with the SEC and are incorporated herein by reference, as well as all other information contained in this prospectus\n",
      "supplement and the accompanying prospectus and incorporated by reference and any free writing prospectus that we have authorized\n",
      "for use in connection with this offering. The risks and uncertainties described below and in our most recent Annual Report on\n",
      "Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, are not the only risks and uncertainties\n",
      "we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our\n",
      "business operations. If any of the risks described below or in our most recent Annual Report on Form 10-K, as revised or supplemented\n",
      "by our subsequent Quarterly Reports on Form 10-Q, actually occur, our business, financial condition and results of operations\n",
      "could suffer. As a result, the trading price of our stock could decline, perhaps significantly, and you could lose all or part\n",
      "of your investment. The risks discussed below and in most recent Annual Report on Form 10-K, as revised or supplemented by our\n",
      "subsequent Quarterly Reports on Form 10-Q, also include forward-looking statements and our actual results may differ substantially\n",
      "from those discussed in these forward-looking statements. See the section entitled “Forward-Looking Information.”\n",
      "1272 158  \n",
      "1277 161  \n",
      "1279 161 We\n",
      "have incurred significant losses since our inception and expect to continue to experience losses for the foreseeable future.\n",
      "1310 140  \n",
      "1312 177 We\n",
      "will need to raise additional capital in the future to complete the development and commercialization of our product candidates\n",
      "and operate our business.\n",
      "1504 161  \n",
      "1506 161 The\n",
      "market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in\n",
      "substantial losses for investors.\n",
      "1714 161  \n",
      "1716 161 If\n",
      "you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution in the net\n",
      "tangible book value of your shares. In addition, we may issue additional securities in the future, which may result in additional\n",
      "dilution to investors.\n",
      "1721 158  \n",
      "1736 161 Our\n",
      "management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not\n",
      "yield a significant return.\n",
      "1740 158  \n",
      "1751 161 Future\n",
      "sales of our common stock in the public market could cause our stock price to fall.\n",
      "1809 161 We\n",
      "cannot assure you that we will continue to be listed on the NYSE American.\n",
      "1828 161 If\n",
      "our common stock is not listed on a national securities exchange, U.S. holders of warrants may not be able to exercise their warrants\n",
      "without compliance with applicable state securities laws and the value of your warrants may be significantly reduced.\n",
      "2860 158 The\n",
      "items in the following summary are described in more detail elsewhere in this prospectus and in the documents incorporated by\n",
      "reference herein. This summary provides an overview of selected information and does not contain all the information you should\n",
      "consider before investing in our common stock. Therefore, you should read the entire prospectus and any free writing prospectus\n",
      "that we have authorized for use in connection with this offering carefully, including the “Risk Factors” section and\n",
      "other documents or information included or incorporated by reference in this prospectus before making any investment decision.\n",
      "2867 158  \n",
      "2886 158 Our\n",
      "Oral Mucositis Product Candidate-Clinical\n",
      "3008 158 Our\n",
      "Antibiotic Product Candidate-Preclinical\n",
      "3061 0 Clostridium difficile (“C. diff”)\n",
      "3070 92 C. diff\n",
      "3071 121 C.\n",
      "diff\n",
      "3072 125 C.\n",
      "diff\n",
      "3074 6 C. diff\n",
      "3086 158 Other\n",
      "Product Candidates and Technologies.\n",
      "3089 158  \n",
      "3278 161  \n",
      "3280 161 Common\n",
      "Stock\n",
      "3299 161 Warrants\n",
      "3299 180 .\n",
      "\n",
      "3334 158 Investing\n",
      "in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the\n",
      "heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus,\n",
      "and under similar headings in our Annual Report on Form 10-K for the year ended December 31, 2018, as updated by any subsequently\n",
      "filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether to\n",
      "purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each\n",
      "of the risk factors described in the documents referenced above could adversely affect our business, operating results and financial\n",
      "condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks\n",
      "might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe\n",
      "are immaterial may also significantly impair our business operations.\n",
      "3345 158  \n",
      "3588 158 Authorized\n",
      "Capital Stock\n",
      "3591 158  \n",
      "3600 158 Reverse\n",
      "Stock Split\n",
      "3603 158  \n",
      "3618 158 Voting\n",
      "3620 158  \n",
      "3630 158 Dividends\n",
      "3632 158  \n",
      "3647 158 Other\n",
      "Rights\n",
      "3650 158  \n",
      "3672 140  \n",
      "3674 161 Fully\n",
      "Paid and Nonassessable\n",
      "3677 161  \n",
      "3705 161 Series\n",
      "A Convertible Preferred Stock\n",
      "3708 161  \n",
      "3732 158 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "3735 158  \n",
      "3745 158 Dividends\n",
      "3747 158  \n",
      "3761 137  \n",
      "3763 158 Liquidation\n",
      "Preference\n",
      "3766 158  \n",
      "3778 158 Ranking\n",
      "3780 158  \n",
      "3797 158 Redemption\n",
      "3799 158  \n",
      "3809 158 Conversion\n",
      "Rights\n",
      "3812 158  \n",
      "3833 158 Adjustments\n",
      "to Conversion Price to Prevent Dilution\n",
      "3836 158  \n",
      "3845 158 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series A Convertible Preferred Stock\n",
      "3848 158  \n",
      "3867 137  \n",
      "3869 158 Registration\n",
      "Rights\n",
      "3872 158  \n",
      "3881 161 Series\n",
      "B Convertible Preferred Stock\n",
      "3884 161  \n",
      "3906 158 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "3909 158  \n",
      "3919 158 Dividends\n",
      "3921 158  \n",
      "3929 158 Liquidation\n",
      "Preference\n",
      "3932 158  \n",
      "3947 158 Ranking\n",
      "3949 158  \n",
      "3974 158 Redemption\n",
      "3976 158  \n",
      "3986 158 Conversion\n",
      "Rights\n",
      "3989 158  \n",
      "4009 158 Adjustments\n",
      "to Conversion Price to Prevent Dilution\n",
      "4012 158  \n",
      "4021 158 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series B Convertible Preferred Stock\n",
      "4024 158  \n",
      "4039 158 Registration\n",
      "Rights\n",
      "4042 158  \n",
      "4057 140  \n",
      "4059 161 Series\n",
      "C Non-Voting\n",
      "4060 25 Non-Convertible Preferred Stock\n",
      "4089 158 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "4092 158  \n",
      "4101 158 Dividends\n",
      "4103 158  \n",
      "4116 158 Liquidation\n",
      "Preference\n",
      "4119 158  \n",
      "4141 137  \n",
      "4143 158 Ranking\n",
      "4145 158  \n",
      "4161 158 Redemption\n",
      "4163 158  \n",
      "4173 158 No\n",
      "Conversion Rights\n",
      "4176 158  \n",
      "4184 158 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series C Non-Voting, Non-Convertible Preferred Stock\n",
      "4187 158  \n",
      "4203 161 Series\n",
      "D Preferred Stock-Converted to Common Stock\n",
      "4206 161  \n",
      "4257 11 L. lactis\n",
      "4340 158 Intrexon\n",
      "Corporation.\n",
      "4353 158 Series\n",
      "A Preferred Stock Private Placement\n",
      "4361 158 Series\n",
      "B Preferred Stock Private Placement\n",
      "4384 158 Florida\n",
      "Law\n",
      "4387 158  \n",
      "4397 158 Articles\n",
      "of Incorporation and Bylaw Provisions\n",
      "4400 158  \n",
      "4743 161 Units\n",
      "4745 161  \n",
      "5483 44 http://www.sec.gov\n",
      "5488 85 www.Oragenics.com \n"
     ]
    }
   ],
   "source": [
    "for line in soup.find_all('i'):\n",
    "    print(line.sourceline, line.sourcepos, line.string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "12 0  \n",
      "14 0 None\n",
      "16 0 Filed\n",
      "Pursuant to Rule 424(b)(5)\n",
      "19 0 Registration\n",
      "No. 333-235763\n",
      "22 0 None\n",
      "24 0  \n",
      "26 0 PROSPECTUS\n",
      "SUPPLEMENT\n",
      "29 0 (To\n",
      "Prospectus dated January 13, 2020)\n",
      "32 0  \n",
      "34 0 None\n",
      "36 0  \n",
      "38 0 None\n",
      "41 0  \n",
      "43 0 Pursuant\n",
      "to this prospectus supplement and the accompanying prospectus, we are offering shares of our common stock, par value $0.001 per\n",
      "share, (the “Common Stock”).\n",
      "47 0  \n",
      "49 0 Our\n",
      "common stock is listed on the NYSE American under the symbol “OGEN.” The last reported sale price of our common stock\n",
      "on the NYSE American on November 19, 2020 was $0.526 per share. We have applied to list the shares being sold in\n",
      "this offering on the NYSE American. There can be no assurances that the NYSE American will grant the application.\n",
      "54 0  \n",
      "56 0 Investing\n",
      "in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of material\n",
      "risks of investing in our common stock under the heading “Risk Factors” beginning on page S-9 of this prospectus supplement\n",
      "and the documents incorporated by reference herein and the accompanying prospectus.\n",
      "61 0  \n",
      "63 0 Neither\n",
      "the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or determined\n",
      "if this prospectus supplement or the prospectus to which it relates is truthful or complete. Any representation to the contrary\n",
      "is a criminal offense.\n",
      "68 0  \n",
      "90 0  \n",
      "111 0  \n",
      "113 0 We\n",
      "have granted the underwriter an option for a period of 45 days from the date of this prospectus supplement to purchase up to 2,128,378\n",
      "additional shares of common stock from us at the public offering price of $0.37 per share of our common stock, less\n",
      "underwriting discounts and commissions. If the underwriter exercises this option in full, the total underwriting discounts and\n",
      "commissions will be $422,625 and total proceeds, before expenses, to us will be $5,614,875.\n",
      "119 0  \n",
      "121 0 We\n",
      "expect that delivery of the shares of our Common Stock being offered pursuant to this prospectus supplement and the accompanying\n",
      "prospectus will be made to purchasers through the facilities of The Depository Trust Company on or about November 24, 2020.\n",
      "125 0  \n",
      "127 0 A.G.P.\n",
      "129 0  \n",
      "131 0 The\n",
      "date of this prospectus supplement is November 19, 2020\n",
      "134 0  \n",
      "142 0  \n",
      "144 0 TABLE\n",
      "OF CONTENTS\n",
      "147 0 Prospectus\n",
      "Supplement\n",
      "150 0  \n",
      "209 0  \n",
      "270 0  \n",
      "277 0  \n",
      "279 0 None\n",
      "282 0  \n",
      "284 0 This\n",
      "prospectus supplement and the accompanying prospectus form part of a registration statement on Form S-3 that we filed with the\n",
      "Securities and Exchange Commission, or the “SEC,” using a “shelf” registration process. This document\n",
      "contains two parts. The first part consists of this prospectus supplement, which provides you with specific information about\n",
      "this offering. The second part, the accompanying prospectus, provides more general information, some of which may not apply to\n",
      "this offering. Generally, when we refer only to the “prospectus,” we are referring to both parts combined. This prospectus\n",
      "supplement, and the information incorporated herein by reference, may add, update or change information in the accompanying prospectus.\n",
      "You should read the entire prospectus supplement as well as the accompanying prospectus and the documents incorporated by reference\n",
      "herein that are described under the headings “Where You Can Find More Information” and “Incorporation of Certain\n",
      "Documents by Reference.” If there is any inconsistency between the information in this prospectus supplement and the accompanying\n",
      "prospectus, you should rely on the information in this prospectus supplement.\n",
      "296 0  \n",
      "298 0 You\n",
      "should rely only on the information contained in this prospectus supplement and the accompanying prospectus, including the information\n",
      "incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that\n",
      "we have authorized for use in connection with this offering. We have not authorized anyone to provide you with information that\n",
      "is different.\n",
      "304 0  \n",
      "306 0 The\n",
      "information contained in this prospectus supplement and the accompanying prospectus, including the information incorporated by\n",
      "reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized\n",
      "for use in connection with this offering is accurate only as of the respective dates thereof, regardless of the time of delivery\n",
      "of this prospectus supplement, the accompanying prospectus or free writing prospectus, if any, or of any sale of our securities.\n",
      "It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus,\n",
      "including the information incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free\n",
      "writing prospectus that we have authorized for use in connection with this offering in making your investment decision. You should\n",
      "also read and consider the information in the documents to which we have referred you in the sections entitled “Where You\n",
      "Can Find More Information” and “Incorporation of Certain Documents by Reference” in this prospectus supplement.\n",
      "317 0  \n",
      "319 0 We\n",
      "are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The\n",
      "distribution of this prospectus supplement and the accompanying prospectus and the offering of securities in certain jurisdictions\n",
      "may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying\n",
      "prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution\n",
      "of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying\n",
      "prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy,\n",
      "any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which\n",
      "it is unlawful for such person to make such an offer or solicitation.\n",
      "329 0  \n",
      "331 0 The\n",
      "industry and market data and other statistical information contained in this prospectus supplement, the accompanying prospectus\n",
      "and the documents we incorporate by reference are based on management’s estimates, independent publications, government\n",
      "publications, reports by market research firms or other published independent sources, and, in each case, are believed by management\n",
      "to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information.\n",
      "None of the independent industry publications used in this prospectus supplement, the accompanying prospectus or the documents\n",
      "we incorporate by reference were prepared on our or our affiliates’ behalf and none of the sources cited by us consented\n",
      "to the inclusion of any data from its reports, nor have we sought their consent.\n",
      "340 0  \n",
      "342 0 We\n",
      "further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any\n",
      "document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including,\n",
      "in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,\n",
      "warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.\n",
      "Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state\n",
      "of our affairs.\n",
      "350 0  \n",
      "352 0 References\n",
      "to, “we,” “us,” “our company,” “Oragenics,” the “Company,” and similar\n",
      "terms refer to Oragenics, Inc., a Florida corporation, unless the context otherwise requires.\n",
      "356 0  \n",
      "364 0  \n",
      "366 0 None\n",
      "369 0  \n",
      "371 0 Certain\n",
      "statements in this prospectus supplement, the accompanying prospectus and documents incorporated by reference herein that look\n",
      "forward in time or express management’s expectations or beliefs with respect to the occurrence of future events are forward-looking\n",
      "statements as defined under within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and\n",
      "Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act, as amended, and are subject to the safe harbor\n",
      "created therein for forward-looking statements. Such statements include, but are not limited to, (i) projections of revenue, earnings,\n",
      "capital structure and other financial items, (ii) statements of our plans and objectives, (iii) statements of expected future\n",
      "economic performance, and (iv) assumptions underlying statements regarding us or our business. Forward-looking statements can\n",
      "be identified by, among other things, the use of forward-looking language, such as “believes,” “expects,”\n",
      "“estimates,” “may,” “will,” “should,” “could,” “seeks,”\n",
      "“plans,” “intends,” “anticipates” or “scheduled to” or the negatives of those\n",
      "terms, or other variations of those terms or comparable language, including, notably, language concerning the “impact”\n",
      "or “limitations” relating to COVID-19, or by discussions of strategy or other intentions, particularly as they relate\n",
      "to the development and funding of our new TerraCoV2 vaccine product candidate.\n",
      "386 0  \n",
      "388 0 We\n",
      "caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking\n",
      "statements as a result of various factors including, but not limited to, the following risks and the other factors described in\n",
      "the Risk Factors section of our annual report on Form 10-K, in our quarterly reports on Form 10-Q and in our Current\n",
      "Reports on Form 8-K incorporated by reference. These factors include:\n",
      "394 0  \n",
      "511 0  \n",
      "518 0  \n",
      "685 0  \n",
      "687 0 We\n",
      "cannot assure you that we have identified all the factors that create uncertainties. Moreover, new risks emerge from time to time\n",
      "and it is not possible for our management to predict all risks, nor can we assess the impact of all risks on our business or the\n",
      "extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking\n",
      "statements. Except as required by law, we undertake no obligation to publicly release the result of any revision of these forward-looking\n",
      "statements to reflect events or circumstances after the date of this prospectus or the respective dates of documents incorporated\n",
      "by reference herein or therein that include forward-looking statements.\n",
      "695 0  \n",
      "697 0 None\n",
      "709 0  \n",
      "711 0 This\n",
      "prospectus supplement also contains estimates, projections and other information concerning our industry, the market and our business.\n",
      "Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties\n",
      "and actual events or circumstances may differ materially from events and circumstances reflected in this information. We obtained\n",
      "the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as\n",
      "from industry and general publications and research surveys and studies conducted by third parties.\n",
      "718 0  \n",
      "726 0  \n",
      "730 0  \n",
      "732 0 None\n",
      "735 0  \n",
      "737 0 This\n",
      "summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the\n",
      "accompanying prospectus. This summary may not contain all of the information that may be important to you. You should read this\n",
      "prospectus supplement, the accompanying prospectus, the information incorporated by reference in each, and any related free writing\n",
      "prospectus before making an investment decision. You should pay special attention to the “Risk Factors” section beginning\n",
      "on page S-9 of this prospectus supplement and “Risk Factors” set forth in our most recent annual report on Form 10-K\n",
      "for the year ended December 31, 2019, as updated by our recent Form 8-K Report filed with the Securities and Exchange Commission\n",
      "on May 8, 2020 and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30,\n",
      "2020, respectively and in the other documents which are incorporated by reference in this prospectus supplement and the accompanying\n",
      "prospectus in their entirety to determine whether an investment in our common stock is appropriate for you.\n",
      "748 0  \n",
      "750 0 Overview\n",
      "752 0  \n",
      "754 0 We\n",
      "are focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further\n",
      "development of novel antibiotics against infectious disease.\n",
      "758 0  \n",
      "760 0 None\n",
      "763 0  \n",
      "765 0 As\n",
      "a result of our acquisition of one hundred percent (100%) of the total issued and outstanding common stock of Noachis Terra, Inc.\n",
      "(“Noachis Terra”) we are now dedicated to the development and commercialization of a vaccine product candidate to\n",
      "provide specific, long lasting immunity from the novel Severe Acute Respiratory Syndrome coronavirus (“SARS-CoV-2”),\n",
      "which causes the coronavirus disease 2019 (“COVID-19”). Noachis Terra is a party to a worldwide, nonexclusive intellectual\n",
      "property and biological materials license agreement with the National Institute of Allergy and Infectious Diseases (“NIAID”),\n",
      "an institute within the National Institutes of Health (“NIH”), relating to certain research, patent applications and\n",
      "biological materials involving pre-fusion coronavirus spike proteins and their use in the development and commercialization of\n",
      "vaccine to provide specific, long lasting immunity from SARS-CoV-2.\n",
      "775 0  \n",
      "777 0 Coronaviruses\n",
      "are a family of viruses that can, when transmitted to humans, lead to upper-respiratory infections. Recent clinical reports also\n",
      "suggest that the SARS-CoV-2 virus can affect other body-systems, including the nervous, cardiovascular, gastrointestinal and renal\n",
      "systems. Among the recent iterations of coronaviruses to move from animal to human carriers is SARS-CoV-2 (often referred to as\n",
      "COVID-19), which, beginning in Wuhan, China, in late 2019, caused a global pandemic due to its rapid spread and the relatively\n",
      "high mortality rate (as compared to the seasonal influenza). In early October of 2020, the World Health Organization’s estimates\n",
      "indicate the number of worldwide COVID-19 infections have exceeded 36,000,000 and the number of deaths directly attributed to\n",
      "COVID-19 have exceeded 1,000,000. Aside from Remdesivir, no governmental regulatory authority in the United States has\n",
      "approved a vaccine or anti-viral treatment specifically targeting SARS-CoV-2 or COVID-19. We intend to combine the research,\n",
      "patent applications and biological materials covered by our NIAID license with our existing clinical research and manufacturing\n",
      "capabilities to respond rapidly to this ongoing, global, public health crisis.\n",
      "789 0  \n",
      "791 0 Coronaviruses, such as SARS -CoV-2, possess signature protein spikes on their outer capsule. The NIAID license covers patents and data\n",
      "on a vaccine candidate that were created based on a stabilized pre-fusion spike trimeric protein. By stabilizing the spike protein\n",
      "in the pre-fusion state, the number of immunogenic centers is increased thereby allowing for a greater likelihood of successful\n",
      "antibody binding, resulting in an improved immunogenic response. The genetic code, acquired from the NIH, for the stabilized pre-fusion\n",
      "spike protein was provided to Aragen Bioscience, Inc. (“Aragen”) for the purpose of insertion of the spike protein\n",
      "gene sequence into a Chinese Hamster Ovary (“CHO”) cell line. Aragen is a leading contract research organization focused\n",
      "on accelerating preclinical biologics product development, has extensive experience building CHO cell lines for recombinant proteins,\n",
      "such as monoclonal antibodies. Aragen has successfully inserted the NIH pre-fusion spike protein gene sequence into a CHO cell\n",
      "line and is currently developing both the analytical tests and identifying preliminary cell line growth conditions to optimize\n",
      "the spike protein titers. Currently, “mini-pool” production and analytical development is underway. The transfer to\n",
      "full-scale manufacture has begun.\n",
      "803 0 None\n",
      "807 0  \n",
      "815 0  \n",
      "819 0  \n",
      "821 0 The\n",
      "NIH’s preclinical study shows that this spike protein, adjuvanted with the mouse specific TLR-4-agonist Sigma Adjuvant System\n",
      "(“SAS”, a TLR-4 agonists) that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus\n",
      "neutralization assay and a plaque reduction neutralization titer (PRNT) assay. In October 2020, we received feedback to our Type\n",
      "B Pre-IND Meeting Request from the FDA. The response indicated that the FDA broadly supported our planned approach to the pre-clinical\n",
      "program that will support the clinical development of the Terra CoV-2, vaccine. As a result, we believe the timelines for both\n",
      "filing an Investigational New Drug (“IND”) application and the commencement of the Phase 1 study will proceed on schedule.\n",
      "We anticipate filing the IND in the second quarter of 2021 and immediately upon the receipt of approval from the FDA, commencing\n",
      "the Phase 1 clinical study.\n",
      "831 0  \n",
      "833 0 We\n",
      "expect to use our currently available cash resources to continue to advance the development of TerraCoV2 with full development\n",
      "being contingent upon the receipt of additional equity funding.\n",
      "837 0  \n",
      "839 0 Our\n",
      "Antibiotic Product Candidate-OG716\n",
      "842 0  \n",
      "844 0 None\n",
      "850 0  \n",
      "852 0 In\n",
      "nonclinical testing, MU1140 has shown activity against all Gram-positive bacteria against which it has been tested, including\n",
      "those responsible for a number of healthcare associated infections, or HAIs. A high percentage of hospital-acquired infections\n",
      "are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative\n",
      "bacteria. We believe the need for novel antibiotics is increasing as a result of the growing resistance of target pathogens to\n",
      "existing FDA approved antibiotics on the market along with the increased use of currently available antibiotics due to secondary\n",
      "infections in SARS-CoV-2 infected patients.\n",
      "860 0  \n",
      "862 0 Lantibiotics\n",
      "have been difficult to investigate for their clinical usefulness as therapeutic agents in the treatment of infectious diseases\n",
      "due to a general inability to produce or synthesize sufficient quantities of pure amounts of these molecules. Traditional fermentation\n",
      "methods can only produce minute amounts of the lantibiotic.\n",
      "867 0  \n",
      "869 0 In\n",
      "June 2012, we entered into the Lantibiotic Exclusive Channel Collaboration Agreement (“Lantibiotic ECC”) with\n",
      "Precigen for the development and commercialization of the native strain of MU1140 and related homologs using Precigen’s\n",
      "advanced transgene and cell engineering platforms. Through our work with Precigen, we have been able to produce a significant\n",
      "increase in the fermentation titer of MU1140 compared to standard fermentation methods and have discovered a new purification\n",
      "process for MU1140. Our work with Precigen generated a substantial number of homologs of MU1140. In January 2020, Precigen\n",
      "consummated a reorganization of its ongoing API fermentation operations and assets into EGI which at the time was an affiliate\n",
      "of Precigen. In connection with the reorganization, Precigen assigned the Lantibiotic ECC and related stock issuance agreements\n",
      "to EGI. Following such reorganization, Precigen divested certain of its assets to TS Biotechnology Holdings, LLC which included\n",
      "EGI and shares of Oragenics securities held by Precigen. As a result of such change by Precigen, we expect to continue\n",
      "our research and development and collaboration efforts with EGI to develop potential derivatives of the MU1140 molecule using\n",
      "genetically modified bacteria.\n",
      "882 0  \n",
      "884 0 None\n",
      "893 0 None\n",
      "897 0  \n",
      "905 0  \n",
      "909 0  \n",
      "911 0 None\n",
      "920 0  \n",
      "922 0 The\n",
      "timing of the filing of an IND regarding OG716 is subject to our having sufficient available human, material and financing capital,\n",
      "which includes research subjects, both animal and human, given all of our anticipated needs and expected requirements in connection\n",
      "with our ongoing research and development initiatives. We will continue to advance the OG716 program to the IND filing based on\n",
      "the availability of both human and financial capital. Based upon the current funding available we will continue to conduct some\n",
      "of the requisite studies. While we commenced certain of these studies at the end of 2019, we expect to focus on efficient and\n",
      "cost-effective improvements in the manufacturing process of the product as we move to complete the pre-clinical studies required\n",
      "to support our first in man Phase 1 clinical study.\n",
      "931 0  \n",
      "933 0 Product\n",
      "Candidates\n",
      "936 0  \n",
      "938 0 Through\n",
      "our wholly-owned subsidiary, Noachis Terra, we intend to begin the research and development stage for our new TerraCoV2 vaccine\n",
      "product candidate. We hold a nonexclusive, worldwide intellectual property license agreement for certain research, patent applications\n",
      "and biological materials relating to the use of pre-fusion coronavirus spike proteins for the development and commercialization\n",
      "of a vaccine for SARS-CoV-2.\n",
      "944 0  \n",
      "946 0 Additionally,\n",
      "we are currently working with Eleszto Genetika, Inc. (as an assignee of Precigen) to use its technology to develop lantibiotics.\n",
      "We seek to protect our product candidates through patents and patent applications pursuant to the terms of our license agreements.\n",
      "950 0  \n",
      "952 0 Recent\n",
      "Developments\n",
      "955 0  \n",
      "957 0 None\n",
      "964 0  \n",
      "966 0 None\n",
      "972 0  \n",
      "974 0 None\n",
      "981 0  \n",
      "983 0 None\n",
      "988 0 None\n",
      "992 0  \n",
      "1000 0  \n",
      "1004 0  \n",
      "1006 0 Corporate\n",
      "and Other Information\n",
      "1009 0  \n",
      "1011 0 We\n",
      "were incorporated in November 1996 and commenced operations in 1999. We consummated our initial public offering in June 2003.\n",
      "We have devoted substantially all of our available resources to the commercialization of our products as well as our discovery\n",
      "efforts comprising research and development, clinical trials for our product candidates, protection of our intellectual property\n",
      "and the general and administrative support of these operations. We have generated limited revenues from grants and product sales\n",
      "through June 30, 2016, and have principally funded our operations through the sale of debt and equity securities. In June of 2016,\n",
      "we completed the sale of our consumer probiotics business to ProBiora Health, LLC and as a result, we will no longer generate\n",
      "revenue from sales of consumer probiotic products.\n",
      "1020 0  \n",
      "1022 0 As\n",
      "of September 30, 2020, we had an accumulated deficit of $150,035,900 and we have yet to achieve profitability. We incurred net\n",
      "losses of $22,021,616 and $11,968,726 for the nine months ended September 30, 2020 and 2019, respectively, and we incurred net\n",
      "losses of $15,566,003 and $9,914,141 for the years ended December 31, 2019 and 2018, respectively. We expect to incur significant\n",
      "and increasing operating losses for the foreseeable future as we seek to advance our product candidates through preclinical testing\n",
      "and clinical trials to ultimately obtain regulatory approval and eventual commercialization. We will need to raise additional\n",
      "capital. Adequate additional funding may not be available to us on acceptable terms, or at all. We expect that research and development\n",
      "expenses will increase along with general and administrative costs, as we seek to grow and continue to operate our business. There\n",
      "can be no assurance that additional capital will be available to us on acceptable terms, if at all.\n",
      "1032 0  \n",
      "1034 0 Our\n",
      "executive office is located at, 4902 Eisenhower Boulevard, Suite 125 Tampa, Florida, 33634 and our research facilities are located\n",
      "at 13700 Progress Boulevard, Alachua, Florida 32615. Our telephone number is (813) 286-7900 and our website is http://www.oragenics.com.\n",
      "Information on, or that can be accessed through, our website is not part of this prospectus supplement or the accompany prospectus\n",
      "and should not be relied on in connection with this offering.\n",
      "1040 0  \n",
      "1044 0  \n",
      "1052 0  \n",
      "1054 124  \n",
      "1058 0 None\n",
      "1061 0  \n",
      "1063 0 The\n",
      "following summary contains basic information about our Common Stock and the offering and is not intended to be complete. It does\n",
      "not contain all the information that may be important to you. For a more complete understanding of our Common Stock, you should\n",
      "read the section of the accompanying prospectus entitled “Description of Capital Stock.”\n",
      "1068 0  \n",
      "1124 78 We\n",
      "                                         estimate that our net proceeds from this offering will be approximately $4,673,700\n",
      "                                         after deducting the underwriting discounts and commissions and estimated offering\n",
      "                                         expenses payable by us. We intend to use the net proceeds from this offering primarily\n",
      "                                         to continue funding, our pre-clinical development of our SARS-CoV-2 vaccine, Terra CoV-2\n",
      "                                         and our lantibiotics program and for general corporate purposes, including research and\n",
      "                                         development activities, capital expenditures and working capital.\n",
      "1131 8  \n",
      "1132 8 See\n",
      "        the section titled “Use of Proceeds” in this prospectus supplement.\n",
      "1158 0  \n",
      "1160 0 The\n",
      "number of shares of our Common Stock shown above to be outstanding immediately before and after this offering is based on 61,004,917\n",
      "shares outstanding as of November 6, 2020, and excludes, as of such date:\n",
      "1164 0  \n",
      "1211 0  \n",
      "1213 0 Except\n",
      "as otherwise indicated, all information included or incorporated by reference in this prospectus supplement assumes the following:\n",
      "1216 0  \n",
      "1237 0  \n",
      "1241 0  \n",
      "1249 0  \n",
      "1251 0 None\n",
      "1254 0  \n",
      "1256 0 Before\n",
      "purchasing our common stock you should carefully consider the risk factors set forth below and under the heading “Risk Factors”\n",
      "included in our most recent Annual Report on Form 10-K, as updated by our recent Form 8-K Report filed with the Securities and\n",
      "Exchange Commission on May 8, 2020, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, each of which\n",
      "are on file with the SEC and are incorporated herein by reference, as well as all other information contained in this prospectus\n",
      "supplement and the accompanying prospectus and incorporated by reference and any free writing prospectus that we have authorized\n",
      "for use in connection with this offering. The risks and uncertainties described below and in our most recent Annual Report on\n",
      "Form 10-K, as revised or supplemented by our subsequent Quarterly Reports on Form 10-Q, are not the only risks and uncertainties\n",
      "we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our\n",
      "business operations. If any of the risks described below or in our most recent Annual Report on Form 10-K, as revised or supplemented\n",
      "by our subsequent Quarterly Reports on Form 10-Q, actually occur, our business, financial condition and results of operations\n",
      "could suffer. As a result, the trading price of our stock could decline, perhaps significantly, and you could lose all or part\n",
      "of your investment. The risks discussed below and in most recent Annual Report on Form 10-K, as revised or supplemented by our\n",
      "subsequent Quarterly Reports on Form 10-Q, also include forward-looking statements and our actual results may differ substantially\n",
      "from those discussed in these forward-looking statements. See the section entitled “Forward-Looking Information.”\n",
      "1272 0  \n",
      "1274 0 Risks\n",
      "Related To Our Financial Condition and Need For Additional Capital\n",
      "1277 0  \n",
      "1279 0 We\n",
      "have incurred significant losses since our inception and expect to continue to experience losses for the foreseeable future.\n",
      "1282 0  \n",
      "1284 0 We\n",
      "have incurred significant net losses and negative cash flow in each year since our inception, including net losses of approximately\n",
      " $22.0 million and $12.0 million for the nine months ended September 30, 2020 and September 30, 2019, respectively, and approximately\n",
      "$15.6 million and $11.3 million for the years ended December 31, 2019, and 2018, respectively. As of September 30, 2020, our accumulated\n",
      "deficit was approximately $150.0 million. We have devoted a significant amount of our financial resources to research and development,\n",
      "including our nonclinical development activities and clinical trials. We expect that the costs associated with our plans to begin\n",
      "preclinical research, contract manufacturing and file an IND for our TerraCoV2 vaccine product candidate and the research and\n",
      "development of our product candidates pursuant to our exclusive channel partnerships with Eleszto Genetika, Inc. (an assignee\n",
      "of Precigen) in the area of lantibiotics (“Lantibiotics Program”) will continue to increase the level of our overall\n",
      "expenses significantly going forward. Additionally, our NIAID license also requires the payment of certain recurring and performance-based\n",
      "royalties that may negatively impact our financial capabilities. As a result, we expect to continue to incur substantial net losses\n",
      "and negative cash flow for the foreseeable future. These losses and negative cash flows have had, and will continue to have, an\n",
      "adverse effect on our shareholders’ equity and working capital. Because of the numerous risks and uncertainties associated\n",
      "with product development and commercialization, we are unable to accurately predict the timing or amount of substantial expenses\n",
      "or when, or if, we will be able to generate the revenue necessary to achieve or maintain profitability.\n",
      "1300 0 None\n",
      "1302 0  \n",
      "1310 0  \n",
      "1312 0 We\n",
      "will need to raise additional capital in the future to complete the development and commercialization of our product candidates\n",
      "and operate our business.\n",
      "1316 0  \n",
      "1318 0 Developing\n",
      "and commercializing biopharmaceutical products, including conducting nonclinical studies and clinical trials and establishing\n",
      "manufacturing capabilities, and the progress of our efforts to develop and commercialize our product candidates, including our\n",
      "acquisition of a vaccine product candidate is expensive, and can cause us to use our limited, available capital resources faster\n",
      "than we currently anticipate. We anticipate that our cash resources as of September 30, 2020, together with the proceeds from\n",
      "recent warrant exercises, will be sufficient to fund our operations as presently structured into the first quarter of 2021. Our\n",
      "actual costs may ultimately vary from our current expectations, which could materially impact our use of capital and our forecast\n",
      "of the period of time through which our financial resources will be adequate to support our operations. Our current cash, cash\n",
      "equivalents and short-term investments are not sufficient to fully implement our business strategy and sustain our operations.\n",
      "Accordingly, we will need to seek additional sources of financing and such additional financing may not be available on favorable\n",
      "terms, if at all. Until we can generate a sufficient amount of product revenue, if ever, we expect to finance future cash needs\n",
      "through public or private equity offerings, debt financings or corporate or government collaboration and licensing arrangements.\n",
      "If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete existing nonclinical and planned\n",
      "clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. We expect capital\n",
      "outlays and operating expenditures to increase over the next several years as we expand our infrastructure, and research and development\n",
      "activities. Specifically, we need to raise additional capital to, among other things:\n",
      "1335 0  \n",
      "1341 78 conduct\n",
      "                                                                              preclinical research for our TerraCoV2 vaccine product candidate, file an IND with the FDA and, if approved, engage in Phase\n",
      "                                                                              1 clinical trials;\n",
      "1390 0  \n",
      "1392 0 Our\n",
      "present and future funding requirements will depend on many factors, including:\n",
      "1395 0  \n",
      "1401 78 the\n",
      "                                         current and continued microeconomic impact of the COVID-19 pandemic on our ability,\n",
      "                                         the ability of our third-party contractors and suppliers to meet our development needs,\n",
      "                                         and the ability of government regulators to conduct ordinary business operations in a\n",
      "                                         timely and efficient manner, as well as the pandemic’s broader, macroeconomic impact\n",
      "                                         on the U.S., foreign and global economic markets;\n",
      "1414 78 the\n",
      "                                                                              level of research and development investment budgeted to develop our current and future product candidates through each phase\n",
      "                                                                              of development;\n",
      "1472 0  \n",
      "1474 0 Additional\n",
      "capital may not be available on satisfactory terms, or at all. Furthermore, if we raise additional funds by issuing\n",
      "equity securities, dilution to our existing stockholders could result. Any equity securities issued also may provide for rights,\n",
      "preferences or privileges senior to those of holders of our common stock. If we raise additional funds by issuing debt securities,\n",
      "these debt securities would have rights, preferences and privileges senior to those of holders of our common stock, and the terms\n",
      "of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations\n",
      "and licensing arrangements, we might be required to relinquish significant rights to our technologies or our products under development\n",
      "or grant licenses on terms that are not favorable to us, which could lower the economic value of those programs to us. If adequate\n",
      "funds are not available, we may have to scale back our operations or limit our research and development activities, which may\n",
      "cause us to grow at a slower pace, or not at all, and our business could be adversely affected.\n",
      "1485 0  \n",
      "1493 0  \n",
      "1495 0 In\n",
      "addition, we could be forced to discontinue product development and commercialization of one or more of our product candidates,\n",
      "curtail or forego sales and marketing efforts, and/or forego licensing attractive business opportunities.\n",
      "1499 0  \n",
      "1501 0 Risks\n",
      "Relating to this Offering\n",
      "1504 0  \n",
      "1506 0 The\n",
      "market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in\n",
      "substantial losses for investors.\n",
      "1510 0  \n",
      "1512 0 The\n",
      "trading price for our common stock has been, and we expect it to continue to be, volatile. The price at which our common stock\n",
      "trades depends upon a number of factors, including our historical and anticipated operating results, our financial situation,\n",
      "announcements by us or our competitors, our ability or inability to raise the additional capital we may need and the terms on\n",
      "which we raise it, and general market and economic conditions. Some of these factors are beyond our control. Broad market fluctuations\n",
      "may lower the market price of our common stock and affect the volume of trading in our stock, regardless of our financial condition,\n",
      "results of operations, business or prospects. The closing price of our common stock as reported on the NYSE American had a high\n",
      "price of $1.05 and a low price of $0.36 in the 52-week period ended December 31, 2019 and a high price of $1.49 and a low price\n",
      "of $0.39 from January 1, 2020 through September 30, 2020. Among the factors that may cause the market price of our common stock\n",
      "to fluctuate are the risks described in this “Risk Factors” section and other factors, including:\n",
      "1523 0  \n",
      "1643 0  \n",
      "1650 0  \n",
      "1704 0  \n",
      "1706 0 In\n",
      "addition, the stock markets, in general, NYSE American and the market for biotech companies in particular, may experience a loss\n",
      "of investor confidence. Such loss of investor confidence may result in extreme price and volume fluctuations in our common stock\n",
      "that are unrelated or disproportionate to the operating performance of our business, financial condition or results of operations.\n",
      "These broad market and industry factors may materially harm the market price of our common stock and expose us to securities class\n",
      "action litigation. Such litigation, even if unsuccessful, could be costly to defend and divert management’s attention and\n",
      "resources, which could further materially harm our financial condition and results of operations.\n",
      "1714 0  \n",
      "1716 0 If\n",
      "you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution in the net\n",
      "tangible book value of your shares. In addition, we may issue additional securities in the future, which may result in additional\n",
      "dilution to investors.\n",
      "1721 0  \n",
      "1723 0 The\n",
      "offering price per share of common stock in this offering is considerably more than the net tangible book value per share of our\n",
      "outstanding common stock. As a result, investors purchasing shares of common stock in this offering will pay a price per share\n",
      "that substantially exceeds the value of our tangible assets after subtracting liabilities. Investors will incur immediate dilution\n",
      "of $0.18 per share, based on the public offering price of $0.37 per share and the net tangible book value as of\n",
      "September 30, 2020. For a more detailed discussion of the foregoing, see the section entitled “Dilution” below. To\n",
      "the extent outstanding stock options and warrants are exercised, or convertible preferred stock converted, there will be further\n",
      "dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional\n",
      "equity or convertible debt securities, our then existing shareholders may experience dilution and the new securities may have\n",
      "rights senior to those of our common stock offered in this offering.\n",
      "1734 0  \n",
      "1736 0 Our\n",
      "management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not\n",
      "yield a significant return.\n",
      "1740 0  \n",
      "1742 0 Our\n",
      "management will have broad discretion over the use of proceeds from this offering. We intend to use the net proceeds from this\n",
      "offering to fund of our Terra CoV-2 research and clinical trials for working capital and general corporate purposes. Our management\n",
      "will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your\n",
      "investment decision, to assess whether the proceeds are being used appropriately. The net proceeds may be used for corporate purposes\n",
      "that do not increase our operating results or enhance the value of our common stock.\n",
      "1749 0  \n",
      "1751 0 Future\n",
      "sales of our common stock in the public market could cause our stock price to fall.\n",
      "1754 0  \n",
      "1756 0 The\n",
      "market price of our common stock could decline as a result of sales of substantial amounts of our common stock in the public market,\n",
      "or the perception that these sales could occur. In addition, these factors could make it more difficult for us to raise funds\n",
      "through future offerings of common stock. We have recently issued a significant number of shares of common stock and the number\n",
      "of outstanding shares has increased from 2,738,283 shares as of December 31, 2012 to 61,004,917 as of November 6, 2020. In addition,\n",
      "there were 16,017,133.483 shares of our Preferred stock outstanding which are convertible into shares of our common stock and\n",
      "warrants to purchase an additional 20,513,145 shares of our common stock issuable upon exercise of warrants to investors. There\n",
      "were also 5,801,349 shares issuable upon exercise of options outstanding and an additional 2,207,901 shares available for option\n",
      "grants under our 2012 Equity Incentive Plan.\n",
      "1766 0  \n",
      "1774 0  \n",
      "1776 0 The\n",
      "issuance of shares of our common stock under our 2012 Equity Incentive Plan is covered by Form S-8 registration statements we\n",
      "filed with the Securities and Exchange Commission, or SEC, and upon exercise of the options, such shares may be resold into the\n",
      "market. We have also issued shares of common stock and warrants in connection with previous private placements. Such shares are\n",
      "available for resale as well as certain of the shares of common stock issuable upon exercise of the warrants. We have also issued\n",
      "shares of our common stock in the private placement and financing transaction, which are deemed to be “restricted securities,”\n",
      "as that term is defined in Rule 144 promulgated under the Securities Act of 1933, as amended, or Securities Act, and such shares\n",
      "may be resold pursuant to the provisions of Rule 144. For example, on June 30, 2016 we issued 904,568 restricted shares\n",
      "of our common stock to three accredited investors (Precigen, the KFLP and our Chairman Dr. Telling) in a private placement. The\n",
      "resale of shares acquired from us in private transactions could cause our stock price to decline significantly. In addition, the\n",
      "conversion of outstanding shares of Series A and Series B convertible preferred stock issued in 2017 private placements into common\n",
      "stock and the subsequent sale of shares of common stock could also cause our stock price to decline significantly.\n",
      "1789 0  \n",
      "1791 0 In\n",
      "addition, from time to time, certain of our shareholders may be eligible to sell all or some of their restricted shares of common\n",
      "stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144, subject to certain limitations. In\n",
      "general, pursuant to Rule 144, after satisfying a six-month holding period: (i) affiliated shareholders, or shareholders whose\n",
      "shares are aggregated, may, under certain circumstances, sell within any three-month period a number of securities which does\n",
      "not exceed the greater of 1% of the then-outstanding shares of common stock or the average weekly trading volume of the class\n",
      "during the four calendar weeks prior to such sale and (ii) non-affiliated shareholders may sell without such limitations, in each\n",
      "case provided we are current in our public reporting obligations. Rule 144 also permits the sale of securities by non-affiliates\n",
      "that have satisfied a one-year holding period without any limitation or restriction.\n",
      "1801 0  \n",
      "1803 0 We\n",
      "are unable to estimate the number of shares that may be sold because this will depend on the market price for our common stock,\n",
      "the personal or business circumstances of sellers and other factors.\n",
      "1807 0  \n",
      "1809 0 We\n",
      "cannot assure you that we will continue to be listed on the NYSE American.\n",
      "1812 0  \n",
      "1814 0 Our\n",
      "common stock commenced trading on the NYSE American (formerly the NYSE MKT) on April 10, 2013, and we are subject to certain NYSE\n",
      "American continued listing requirements and standards. We may also incur costs that we have not previously incurred for expenses\n",
      "for compliance with the rules and requirements of the NYSE American. We cannot provide any assurance that we will be able to continue\n",
      "to satisfy the requirements of the NYSE American’s continued listing standards.\n",
      "1820 0  \n",
      "1822 0 A\n",
      "delisting of our common stock from the NYSE American could negatively affect the price and liquidity of our common stock and could\n",
      "impair our ability to raise capital in the future.\n",
      "1826 0  \n",
      "1828 0 If\n",
      "our common stock is not listed on a national securities exchange, U.S. holders of warrants may not be able to exercise their warrants\n",
      "without compliance with applicable state securities laws and the value of your warrants may be significantly reduced.\n",
      "1832 0  \n",
      "1834 0 If\n",
      "our common stock is delisted from the NYSE America and is not eligible to be listed on another national securities exchange, the\n",
      "exercise of the warrants by U.S. holders may not be exempt from state securities laws. As a result, depending on the state of\n",
      "residence of a holder of the warrants, a U.S. holder may not be able to exercise its warrants unless we comply with any state\n",
      "securities law requirements necessary to permit such exercise or an exemption applies. Although we plan to use our reasonable\n",
      "efforts to assure that U.S. holders will be able to exercise their warrants under applicable state securities laws if no exemption\n",
      "exists, there is no assurance that we will be able to do so. As a result, in the event that our common stock is delisted from\n",
      "the NYSE American and is not eligible to be listed on another securities exchange, your ability to exercise your warrants may\n",
      "be limited. The value of the warrants may be significantly reduced if U.S. holders are not able to exercise their warrants under\n",
      "applicable state securities laws.\n",
      "1845 0  \n",
      "1853 0 None\n",
      "1855 0  \n",
      "1857 0 None\n",
      "1859 0  \n",
      "1861 0 The\n",
      "following table sets forth our cash and capitalization as of September 30, 2020:\n",
      "1864 0  \n",
      "1866 0 on\n",
      "an actual basis; and\n",
      "1869 0  \n",
      "1871 0 on\n",
      "an as adjusted basis to give effect to our sale in this offering of 14,189,189 shares of common stock at $0.37 per\n",
      "share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.\n",
      "1875 0  \n",
      "1877 0 You\n",
      "should read this table in conjunction with “Use of Proceeds” as well as our “Management’s Discussion and\n",
      "Analysis of Financial Condition and Results of Operations” and our consolidated financial statements, including the related\n",
      "notes, incorporated by reference into this prospectus supplement and the accompanying prospectus.\n",
      "1882 0  \n",
      "1944 0  \n",
      "1946 0 None\n",
      "1950 0  \n",
      "1952 0 The\n",
      "number of shares of our Common Stock shown above to be outstanding immediately before and after this offering is based on 61,004,917\n",
      "shares outstanding as of September 30, 2020, and excludes, as of such date:\n",
      "1956 0  \n",
      "2002 0  \n",
      "2004 0 Except\n",
      "as otherwise indicated, all information included or incorporated by reference in this prospectus supplement assumes the following:\n",
      "2007 0  \n",
      "2028 0  \n",
      "2036 0  \n",
      "2038 0 None\n",
      "2041 0  \n",
      "2043 0 We\n",
      "estimate that the net proceeds from this offering will be approximately $4,673,700 after deducting our estimated offering\n",
      "expenses payable by us.\n",
      "2047 0  \n",
      "2049 0 None\n",
      "2058 0  \n",
      "2060 0 None\n",
      "2063 0  \n",
      "2065 0 To\n",
      "date, we have neither declared nor paid any dividends on our common stock nor do we anticipate that such dividends will be paid\n",
      "in the foreseeable future. Rather, we intend to retain any earnings to finance the growth and development of our business. Any\n",
      "payment of cash dividends on our common stock in the future will be dependent, among other things, upon our earnings, financial\n",
      "condition, capital requirements and other factors which the board of directors deems relevant. In addition, restrictive covenants\n",
      "contained in any financing agreements entered into in the future may preclude us from paying any dividends.\n",
      "2072 0  \n",
      "2074 0 We\n",
      "issued 100 shares of Series C, Non-Voting, Non-Convertible, Preferred Stock (“Series C Preferred Stock”) with a stated\n",
      "value of $33,847 per share to Precigen in exchange for obligations we owed to Precigen Inc. (“Precigen”). These shares\n",
      "have an accruing dividend of 12% per year payable in additional shares of Series C Preferred Stock. The accruing dividend\n",
      "increased to 20% per year after May 10, 2019. In January of 2018 we paid a dividend on our Series C Preferred Stock to Precigen\n",
      "of 1.733 shares for the portion of the 2017 fiscal year that the Series C Preferred Stock was outstanding and in January\n",
      "of 2019, we paid a dividend on our Series C Preferred Stock to Precigen of 12.208 shares. On January 27, 2020 we paid a dividend\n",
      "on our Series C Preferred Stock to Precigen of 19.542 shares of additional Series C Preferred Stock. As a result of the recent\n",
      "sale by Precigen of its equity interest in Oragenics to TS Biotechnology LLC, future dividend payments will be paid to\n",
      "TS Biotechnology.\n",
      "2085 0  \n",
      "2093 0  \n",
      "2095 0 None\n",
      "2097 0  \n",
      "2099 0 If\n",
      "you invest in our securities, your interest will be diluted to the extent of the difference between the public offering price\n",
      "per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering.\n",
      "2103 0  \n",
      "2105 0 Our\n",
      "net tangible book value as of September 30, 2020 was $9,640,345, or approximately $0.16 per share. Net tangible book value per\n",
      "share is equal to the amount of our total tangible assets, less total liabilities (excludes shares of Series C Preferred Stock\n",
      "with a stated value of $33,847.9874 per share), divided by the aggregate number of shares of our common stock outstanding\n",
      "as of September 30, 2020. Dilution in net tangible book value per share represents the difference between the public offering\n",
      "price per share of our common stock in this public offering and the net tangible book value per share of our common stock immediately\n",
      "after this offering.\n",
      "2113 0  \n",
      "2115 0 After\n",
      "giving effect to the sale of 14,189,189 shares of our common stock in this offering at the public offering price of $0.37\n",
      "per share and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable\n",
      "by us, our as adjusted net tangible book value as of September 30, 2020 would have been approximately $14,314,045, or $0.19\n",
      "per share. This represents an immediate increase in net tangible book value of $0.03 per share to existing stockholders\n",
      "and immediate dilution in net tangible book value of $0.18 per share to new investors purchasing our common stock in this\n",
      "offering at the public offering price. The following table illustrates this dilution on a per share basis:\n",
      "2123 0  \n",
      "2153 0  \n",
      "2155 0 The\n",
      "above discussion and table are based on 61,004,917 shares of our common stock outstanding as of September 30, 2020 and excludes\n",
      "the shares of common stock issuable upon the conversion of our outstanding preferred stock and the shares of common stock issuable\n",
      "upon the exercise of outstanding options and warrants, including the following securities:\n",
      "2160 0  \n",
      "2206 0  \n",
      "2208 0 The\n",
      "above illustration of dilution per share to the investors participating in this offering assumes no exercise of outstanding preferred\n",
      "shares or options or warrants to purchase shares of our common stock. To the extent that options, warrants or preferred shares\n",
      "outstanding as of September 30, 2020 or issued thereafter have been or may be exercised or converted or other shares issued, the\n",
      "investors purchasing shares of our common stock  in this offering may experience further dilution. In addition, we may choose\n",
      "to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for\n",
      "our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible\n",
      "debt securities, the issuance of these securities could result in further dilution to our stockholders.\n",
      "2217 0  \n",
      "2225 0  \n",
      "2227 0 None\n",
      "2229 0  \n",
      "2231 0 Under\n",
      "the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus supplement, the underwriter\n",
      "named below has agreed to purchase, and we have agreed to sell to the underwriter, the number of shares of common stock indicated\n",
      "below.\n",
      "2242 97 14,189,189\n",
      "2245 74 14,189,189\n",
      "2248 0  \n",
      "2250 0 The\n",
      "underwriter is offering the shares of common stock subject to its acceptance of the shares from us and subject to prior sale.\n",
      "The underwriting agreement provides that the obligations of the underwriter to pay for and accept delivery of the shares of common\n",
      "stock offered by this prospectus supplement are subject to the approval of certain legal matters by its counsel and to certain\n",
      "other conditions. The underwriter is obligated to take and pay for all of the shares of common stock offered by this prospectus\n",
      "supplement if any such shares are taken. However, the underwriter is not required to take or pay for the shares covered by the\n",
      "underwriter’s over-allotment option described below.\n",
      "2258 0  \n",
      "2260 0 The\n",
      "underwriter initially proposes to offer part of the shares of common stock directly to the public at the offering price listed\n",
      "on the cover page of this prospectus supplement and part to certain dealers. After the initial offering of the shares of common\n",
      "stock, the offering price, and other selling terms may from time to time be varied by the underwriter.\n",
      "2265 0 None\n",
      "2267 0 We\n",
      "have granted to the underwriter an option, exercisable for 45 days from the date of this prospectus supplement, to purchase additional\n",
      "2,128,378 shares of common stock at the public offering price listed on the cover page of this prospectus supplement, less\n",
      "underwriting discounts and commissions. To the extent the option is exercised, the underwriter will become obligated, subject\n",
      "to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next\n",
      "to the underwriter’s name in the preceding table bears to the total number of shares of common stock listed next to the\n",
      "name of the underwriter in the preceding table.\n",
      "2275 0  \n",
      "2277 0 None\n",
      "2282 98  \n",
      "2282 213 Per\n",
      "                                         Share\n",
      "2283 55 None\n",
      "2284 98 Total\n",
      "                                         Without Over-Allotment\n",
      "2285 72 None\n",
      "2286 98 Total\n",
      "                                         With Over-Allotment\n",
      "2287 69 None\n",
      "2290 97 0.3700\n",
      "2291 97 5,250,000\n",
      "2292 97 6,037,500\n",
      "2295 74 0.0259\n",
      "2296 74 367,500\n",
      "2297 74 422,625\n",
      "2300 74 0.3441\n",
      "2301 74 4,882,500\n",
      "2302 74 5,614,875\n",
      "2305 0  \n",
      "2307 0 The\n",
      "estimated offering expenses payable by us, exclusive of underwriting discounts and commissions, are approximately $208,000.\n",
      "2310 0  \n",
      "2312 0 Our\n",
      "common stock is listed on the NYSE American under the symbol “OGEN.”\n",
      "2315 0  \n",
      "2317 0 We\n",
      "and our directors and executive officers have agreed that, subject to certain exceptions, without the prior written consent of\n",
      "A.G.P./Alliance Global Partners, we, and each of our directors and executive officers will not,\n",
      "for a period of 90 days following the date of this prospectus supplement:\n",
      "2322 0  \n",
      "2335 0 None\n",
      "2337 0  \n",
      "2338 0 None\n",
      "2346 0  \n",
      "2348 0 None\n",
      "2350 0  \n",
      "2372 0  \n",
      "2374 0 In\n",
      "order to facilitate the offering of the shares of common stock, the underwriter may engage in transactions that stabilize, maintain\n",
      "or otherwise affect the price of the shares of common stock. Specifically, the underwriter may sell more shares than it is obligated\n",
      "to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is No greater\n",
      "than the number of shares available for purchase by the underwriter under the option to purchase additional shares. The underwriter\n",
      "can close out a covered short sale by exercising the option to purchase additional shares or by purchasing shares in the open\n",
      "market. In determining the source of shares to close out a covered short sale, the underwriter will consider, among other things,\n",
      "the open market price of shares compared to the price available under the option to purchase additional shares. The underwriter\n",
      "may also sell shares in excess of the option to purchase additional shares, creating a naked short position. The underwriter must\n",
      "close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created\n",
      "if the underwriter is concerned that there may be downward pressure on the price of the shares of common stock in the open market\n",
      "after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this\n",
      "offering, the underwriter may bid for, and purchase, shares of common stock in the open market to stabilize the price of the shares\n",
      "of common stock. These activities may raise or maintain the market price of the shares of common stock above independent market\n",
      "levels or prevent or retard a decline in the market price of the shares of common stock. The underwriter is not required to engage\n",
      "in these activities and may end any of these activities at any time.\n",
      "2391 0  \n",
      "2393 0 We\n",
      "and the underwriter have agreed to indemnify each other against certain liabilities, including liabilities under the Securities\n",
      "Act.\n",
      "2397 0  \n",
      "2399 0 A\n",
      "prospectus in electronic format may be made available on websites maintained by the underwriter, or selling group members, if\n",
      "any, participating in this offering. The underwriter may allocate a number of shares of common stock for sale to its online brokerage\n",
      "account holders. Internet distributions will be allocated by the underwriter that may make Internet distributions on the same\n",
      "basis as other allocations.\n",
      "2405 0  \n",
      "2407 0 The\n",
      "underwriter has in the past provided investment banking and advisory services to us and our affiliates in the ordinary course\n",
      "of business for which it has received compensation for such services. The underwriter may in the future provide investment banking\n",
      "and advisory services to us and our affiliates in the ordinary course of business for which it may receive compensation for such\n",
      "services.\n",
      "2413 0  \n",
      "2415 0 Selling\n",
      "Restrictions\n",
      "2418 0  \n",
      "2420 0 This\n",
      "prospectus supplement does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country\n",
      "or jurisdiction (i) in which such an offer or solicitation is not authorized, (ii) in which any person making such offer or solicitation\n",
      "is not qualified to do so or (iii) in which any such offer or solicitation would otherwise be unlawful. No action has been taken\n",
      "that would, or is intended to, permit a public offer of the securities or possession or distribution of this prospectus supplement\n",
      "or any other offering or publicity material relating to the securities in any country or jurisdiction (other than the United States)\n",
      "where any such action for that purpose is required. Accordingly, the underwriter has undertaken that it will not, directly or\n",
      "indirectly, offer or sell any securities or have in its possession, distribute or publish any prospectus supplement, form of application,\n",
      "advertisement or other document or information in any country or jurisdiction except under circumstances that will, to the best\n",
      "of its knowledge and belief, result in compliance with any applicable laws and regulations and all offers and sales of securities\n",
      "by it will be made on the same terms.\n",
      "2432 0  \n",
      "2438 60  \n",
      "2441 0 None\n",
      "2443 0  \n",
      "2445 0 None\n",
      "2448 0  \n",
      "2450 0 The\n",
      "validity of the issuance of the securities offered hereby will be passed upon for us by Shumaker, Loop & Kendrick, LLP. Certain\n",
      "legal matters in connection with the offering will be passed upon for the underwriter by McDermott Will & Emery LLP.\n",
      "2454 0  \n",
      "2456 0 None\n",
      "2458 0  \n",
      "2460 0 The\n",
      "financial statements incorporated in this prospectus by reference from the Company’s Annual Report on Form 10-K have been\n",
      "audited by Mayer Hoffman McCann P.C., an independent registered public accounting firm, as stated in their report (which report\n",
      "includes an explanatory paragraph relating to the Company’s ability to continue as a going concern), which is incorporated\n",
      "herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their\n",
      "authority as experts in accounting and auditing Mayer Hoffman McCann P.C. has no interest in the shares being registered in this\n",
      "filing.\n",
      "2468 0  \n",
      "2470 0 None\n",
      "2473 0  \n",
      "2475 0 None\n",
      "2477 0 None\n",
      "2481 0 None\n",
      "2483 0  \n",
      "2485 0 In\n",
      "addition, we maintain a web site that contains information regarding our company, including copies of reports, proxy statements\n",
      "and other information we file with the SEC. The address of our web site is www.oragenics.com. Except for the documents specifically\n",
      "incorporated by reference into this prospectus, information contained on our website or that can be accessed through our website\n",
      "does not constitute a part of this prospectus. We have included our website address only as an inactive textual reference and\n",
      "do not intend it to be an active link to our website.\n",
      "2492 0  \n",
      "2494 0 This\n",
      "prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the\n",
      "SEC registering the securities that may be offered and sold hereunder. The registration statement, including exhibits thereto,\n",
      "contains additional relevant information about us and these securities that, as permitted by the rules and regulations of the\n",
      "SEC, we have not included in this prospectus supplement or the accompanying prospectus. A copy of the registration statement can\n",
      "be obtained at the address set forth above. You should read the registration statement for further information about us and these\n",
      "securities.\n",
      "2502 0  \n",
      "2507 60  \n",
      "2510 0  \n",
      "2512 0 None\n",
      "2515 0  \n",
      "2517 0 In\n",
      "this document, we “incorporate by reference” certain information we file with the SEC, which means that we can disclose\n",
      "important information to you by referring to that information. The information incorporated by reference is considered to be a\n",
      "part of this prospectus supplement. Any statement contained in a document incorporated by reference herein shall be deemed to\n",
      "be modified or superseded for all purposes to the extent that a statement contained in this prospectus supplement or in any other\n",
      "subsequently filed document that is also incorporated or deemed to be incorporated by reference, modifies or supersedes such statement.\n",
      "Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this\n",
      "prospectus supplement. We incorporate by reference the documents listed below (other than, in each case, documents or information\n",
      "deemed to be furnished and not filed in accordance with SEC rules):\n",
      "2527 0  \n",
      "2529 0 None\n",
      "2561 0  \n",
      "2563 0 We\n",
      "hereby undertake to provide without charge to each person, including any beneficial owner, to whom a copy of this prospectus supplement\n",
      "is delivered, upon written or oral request of any such person, a copy of any and all of the information that has been or may be\n",
      "incorporated by reference in this prospectus supplement, including any exhibits that are specifically incorporated by reference\n",
      "in such documents. Requests for such copies should be directed as follows:\n",
      "2569 0  \n",
      "2571 0 Oragenics,\n",
      "Inc.\n",
      "2574 0 4902\n",
      "Eisenhower Boulevard, Suite 125\n",
      "2577 0 Tampa,\n",
      "Florida 33634\n",
      "2580 0 Attention:\n",
      "Investor Relations\n",
      "2583 0 Phone:\n",
      "(813) 276-7900\n",
      "2586 0  \n",
      "2591 60  \n",
      "2594 0  \n",
      "2596 0 PROSPECTUS\n",
      "2598 0  \n",
      "2600 0 None\n",
      "2602 0 None\n",
      "2604 0  \n",
      "2606 0 $50,000,000\n",
      "2608 0  \n",
      "2610 0 Common\n",
      "Stock\n",
      "2613 0 Warrants\n",
      "2615 0 Units\n",
      "2617 0  \n",
      "2619 0 From\n",
      "time to time, we may offer, issue and sell up to $50,000,000 of any combination of the securities described in this prospectus.\n",
      "We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities\n",
      "registered hereunder, including any applicable antidilution provisions.\n",
      "2624 0  \n",
      "2626 0 This\n",
      "prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide\n",
      "the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one\n",
      "or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any\n",
      "related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully\n",
      "read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated\n",
      "by reference, before buying any of the securities being offered.\n",
      "2634 0  \n",
      "2636 0 Our\n",
      "common stock is listed on the NYSE American under the symbol “OGEN.” The last reported sale price of our common stock\n",
      "on December 27, 2019 was $0.527 per share. The applicable prospectus supplement will contain information, where applicable, as\n",
      "to any other listing, if any, on the NYSE American or any securities market or other exchange of the securities covered by the\n",
      "applicable prospectus supplement.\n",
      "2642 0  \n",
      "2644 0 As\n",
      "of December 27, 2019, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float,\n",
      "was approximately $27,351,030, which was calculated based on 44,114,566 shares of our outstanding common stock held by non-affiliates\n",
      "and on a price of $0.62 per share, the last reported sale price for our common stock on November 29, 2019. Pursuant to General\n",
      "Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding one-third\n",
      "of our public float in any 12-month period unless our public float subsequently rises to $75.0 million or more.\n",
      "2651 0  \n",
      "2653 0 None\n",
      "2658 0  \n",
      "2660 0 This\n",
      "prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.\n",
      "2663 0  \n",
      "2665 0 The\n",
      "securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters\n",
      "or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section\n",
      "entitled “Plan of Distribution” in this prospectus and in the applicable prospectus supplement. If any agents or underwriters\n",
      "are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents\n",
      "or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement.\n",
      "The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth\n",
      "in a prospectus supplement.\n",
      "2674 0  \n",
      "2676 0 Neither\n",
      "the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or\n",
      "determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.\n",
      "2680 0  \n",
      "2682 0 The\n",
      "date of this prospectus is January 13, 2020.\n",
      "2685 0  \n",
      "2693 0  \n",
      "2695 0 TABLE\n",
      "OF CONTENTS\n",
      "2698 0  \n",
      "2758 0  \n",
      "2765 0  \n",
      "2767 0 None\n",
      "2770 0  \n",
      "2772 0 This\n",
      "prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC,\n",
      "utilizing a “shelf” registration process. Under this shelf registration statement, we may, from time to time, sell\n",
      "any combination of the securities referred to herein in one or more offerings for total gross proceeds of up to $50,000,000. This\n",
      "prospectus provides you with a general description of the securities we may offer.\n",
      "2778 0  \n",
      "2780 0 Until\n",
      "such time, if ever, as we are eligible to use General Instruction I.B.1. of Form S-3, pursuant to General Instruction I.B.6. of\n",
      "Form S-3, we are permitted to use the registration statement of which this prospectus forms a part to sell, via a primary offering,\n",
      "a maximum amount of securities equal to one-third of the aggregate market value of our outstanding voting and non-voting common\n",
      "equity held by non-affiliates of our company in any twelve month period.\n",
      "2786 0  \n",
      "2788 0 None\n",
      "2801 0  \n",
      "2803 0 You\n",
      "should rely only on the information that we have provided or incorporated by reference in this prospectus, any applicable prospectus\n",
      "supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any other\n",
      "person to provide you with different or additional information. No dealer, salesperson or other person is authorized to give any\n",
      "information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free\n",
      "writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation.\n",
      "This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer\n",
      "to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do\n",
      "this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell\n",
      "or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer\n",
      "or solicitation in such jurisdiction.\n",
      "2815 0  \n",
      "2817 0 You\n",
      "should not assume that the information appearing in this prospectus, any applicable prospectus supplement or any related free\n",
      "writing prospectus is accurate on any date subsequent to the date on the front of the document and that any information we have\n",
      "incorporated by reference is accurate the date of the document incorporated by reference, regardless of the time of delivery of\n",
      "this prospectus, any applicable prospectus supplement or any related free writing prospectus or any sale of a security. Our business,\n",
      "financial condition, results of operations and prospectus may have changed since those dates.\n",
      "2824 0  \n",
      "2826 0 This\n",
      "prospectus contains and incorporates by reference market data, industry statistics and other data that have been obtained from,\n",
      "or compiled from, information made available by third parties. We have not independently verified their data. This prospectus\n",
      "and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies.\n",
      "All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus\n",
      "supplement or any related free writing prospectus are the property of their respective owners.\n",
      "2833 0  \n",
      "2835 0 This\n",
      "prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made\n",
      "to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents.\n",
      "Copies of some of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits\n",
      "to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below\n",
      "under the section entitled “Where You Can Find Additional Information” and “Incorporation of Certain Information\n",
      "by Reference.”\n",
      "2843 0  \n",
      "2851 0  \n",
      "2853 0 None\n",
      "2855 0 None\n",
      "2858 0  \n",
      "2860 0 The\n",
      "items in the following summary are described in more detail elsewhere in this prospectus and in the documents incorporated by\n",
      "reference herein. This summary provides an overview of selected information and does not contain all the information you should\n",
      "consider before investing in our common stock. Therefore, you should read the entire prospectus and any free writing prospectus\n",
      "that we have authorized for use in connection with this offering carefully, including the “Risk Factors” section and\n",
      "other documents or information included or incorporated by reference in this prospectus before making any investment decision.\n",
      "2867 0  \n",
      "2869 0 Unless\n",
      "otherwise mentioned or unless the context requires otherwise, all references in this prospectus to “Oragenics” the\n",
      "“Company,” “we,” “our” and “us” or similar references mean Oragenics, Inc. When\n",
      "we refer to “you,” we mean the holders of the applicable securities.\n",
      "2874 0  \n",
      "2876 0 Overview\n",
      "2878 0  \n",
      "2880 0 We\n",
      "are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral\n",
      "mucositis.\n",
      "2884 0  \n",
      "2886 0 Our\n",
      "Oral Mucositis Product Candidate-Clinical\n",
      "2889 0  \n",
      "2891 0 In\n",
      "June of 2015, we entered into a worldwide Exclusive Channel Collaboration Agreement (“Oral Mucositis ECC”) with Intrexon\n",
      "Corporation (“Intrexon”) and Intrexon Actobiotics NV, a wholly-owned subsidiary of Intrexon, pursuant to which we\n",
      "obtained certain exclusive rights to AG013 as a potential treatment of oral mucositis, or OM for cancer patients, which we intend\n",
      "to continue to develop. AG013, is an oral rinsing solution system designed to deliver human Trefoil Factor 1 (hTFF1) to protect\n",
      "and regenerate damaged mucosal lining of the oral cavity.\n",
      "2898 0  \n",
      "2900 0 OM\n",
      "results in a painful inflammation and mucosal ulceration in the lining of the oral cavity, throat and esophagus and is one of\n",
      "the most commonly reported adverse events associated with cancer chemotherapy. Approximately 770,000 patients annually in the\n",
      "US are at an increased risk of developing OM according to cancer statistics provided by the Center for Disease Control (CDC) in\n",
      "2017. OM has a negative effect on patient well-being and if severe, negatively affects adherence to a patient’s cancer treatment\n",
      "regimen. At present, we are not aware of any drug that is approved to prevent the condition broadly and current therapies are\n",
      "primarily palliative in nature, only addressing symptom relief but not treating the underlying causes of the condition.\n",
      "2908 0  \n",
      "2910 0 AG013\n",
      "has been granted Orphan Drug status in the European Union. In November of 2016, the United States Food and Drug Administration\n",
      "(the “FDA”) granted Fast Track designation for AG013, and we believe it may be eligible for Biologic License Application\n",
      "(“BLA”) exclusivity as well. The FDA’s fast track therapy designation program is intended to facilitate the\n",
      "development and expedite the review of drug candidates intended for the treatment of serious or life-threatening conditions and\n",
      "that demonstrate the potential to address unmet medical needs for those conditions. Under this program, FDA can, for example,\n",
      "review portions of a New Drug Application or BLA for a drug candidate before the entire application is complete, thus potentially\n",
      "beginning the review process at an earlier time.\n",
      "2919 0  \n",
      "2921 0 None\n",
      "2929 0  \n",
      "2937 0  \n",
      "2939 0 We\n",
      "developed a Phase 2 protocol for AG013 with the FDA under the fast track designation. In August of 2016, we received feedback\n",
      "from the FDA in response to our Type C meeting and the pursuit of a Phase 2 trial on AG013 for the treatment of oral mucositis\n",
      "in head and neck cancer patients. We filed an Investigational New Drug (“IND”) update in March 2017 and we initiated\n",
      "the Phase 2 study with AG013 in the United States in 2017 and in Europe in 2018. The Phase 2 trial was a double-blind, placebo-controlled,\n",
      "2-arm, multi-center trial in which approximately 200 patients were randomized in a 1:1 ratio to receive either a placebo or AG013\n",
      "following meals, beginning on the first day of chemoradiation therapy and continuing through the course of cancer treatment. The\n",
      "study enrolled patients receiving chemoradiation for treatment of head and neck cancer for 7 to 9 weeks. The clinical trial was\n",
      "conducted at clinical sites across the United States and Europe. The purpose of the Phase 2 study (NCT03234465) is to evaluate\n",
      "the efficacy (preventing the occurrence and shortening the duration of severe oral mucositis (“SOM”), safety and tolerability\n",
      "of topically administered AG013 rinse compared to the placebo for reducing the incidence and severity of OM in patients undergoing\n",
      "traditional chemoradiation for the treatment of head and neck cancer. Key efficacy measures include collection of data regarding\n",
      "the duration, time to development, and overall incidence of OM (World Health Organization scale used) during the active treatment\n",
      "phase, beginning from the start of chemoradiation therapy until 2 weeks following its completion.\n",
      "2954 0  \n",
      "2956 0 None\n",
      "2960 0  \n",
      "2962 0 An\n",
      "interim safety analysis was requested by the FDA on patients from our Phase 2 clinical trial of AG013 for the treatment of OM.\n",
      "We completed enrollment of the interim safety analysis cohort, which included 24 randomized patients in our Phase 2 clinical trial\n",
      "of AG013 for the treatment OM. Nineteen of those patients were included in the unblinded safety evaluation, of which 10 received\n",
      "AG013. We announced positive results from our interim safety analysis in May, 2018. The study provided information that, we believe,\n",
      "likely indicates that the overall incidence of severe OM is less than would be anticipated in the general head and neck cancer\n",
      "population.\n",
      "2970 0  \n",
      "2972 0 Safety\n",
      "was evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examinations, clinical laboratory\n",
      "assessments and the presence of AG013 in whole blood. Tolerability measures (taste, consistency and smell) were collected from\n",
      "the patient diaries. In addition, the reasons for study treatment discontinuation were also summarized. Following review of the\n",
      "data by an independent Data Safety Monitoring Board (DSMB), it was concluded that the clinical trial can proceed with no changes\n",
      "to the study. The data analysis indicated that the distribution of adverse events was similar between AG013 and placebo. The serious\n",
      "adverse events reported were consistent with those commonly reported in a head and neck cancer population receiving traditional\n",
      "chemoradiation therapy treatments and included fevers, neutropenia, anemia, nausea and vomiting, infections and oral (mouth and\n",
      "throat) pain and there were no reports of AG013 related bacteremia or sepsis. Of patients that discontinued participation in the\n",
      "clinical study, 4 patients experienced adverse events, including 3 patients who developed nausea and vomiting, 2 patients that\n",
      "were non-compliant with the study procedures and 3 patients developed severe OM.\n",
      "2984 0  \n",
      "2986 0 The\n",
      "DSMB met again in September 2019 and reviewed safety data on the first 100 patients who completed the trial and determined that\n",
      "the clinical trial could continue with no adjustments or further review.\n",
      "2990 0  \n",
      "2992 0 On\n",
      "September 30, 2019, we made a poster presentation at the European Society for Medical Oncology Congress where we announced initial\n",
      "blinded blended data from our Phase 2, placebo-controlled, clinical trial of AG013 in oral mucositis. The presentation described\n",
      "the methods and initial blinded results from the ongoing Phase 2 clinical trial for our lead oral mucositis product candidate,\n",
      "AG013. The initial blinded data, submitted in the abstract, reflected the results for 42 of the 71 enrolled and randomized patients\n",
      "across 48 study sites who had completed their treatment course and demonstrated that in the blinded, combined placebo and active\n",
      "treatment groups, there was sufficient evidence of efficacy and safety to continue the study. Additional data accumulated since\n",
      "poster submission, indicated the blinded efficacy evaluation, which included any patient with SOM after week one of treatment\n",
      "and those receiving a cumulative dose of 55 Gy (week 6 of treatment), demonstrated an overall SOM incidence of 47%, which we believe\n",
      "is lower than would be expected based on historical data in the head and neck cancer population receiving this chemoradiation\n",
      "regimen. The overall rate of SOM was reported in only 13.1% (110 of 842) of evaluable visits. The overall safety profile continues\n",
      "to be consistent with those adverse events that normally occur in cancer patients receiving chemoradiation therapy. The study,\n",
      "however, remains blinded and individual treatment responses remain to be identified.\n",
      "3006 0  \n",
      "3008 0 Our\n",
      "Antibiotic Product Candidate-Preclinical\n",
      "3011 0  \n",
      "3013 0 Members\n",
      "of our scientific team discovered that a certain bacterial strain produces MU1140, a molecule belonging to the novel class of\n",
      "antibiotics known as lantibiotics. Lantibiotics, such as MU1140, are highly modified peptide antibiotics made by a small group\n",
      "of Gram-positive bacterial species. Approximately 60 lantibiotics have been discovered, to date. We believe lantibiotics are generally\n",
      "recognized by the scientific community to be potent antibiotic agents.\n",
      "3019 0  \n",
      "3021 0 None\n",
      "3028 0  \n",
      "3030 0 In\n",
      "nonclinical testing, MU1140 has shown activity against all Gram-positive bacteria against which it has been tested, including\n",
      "those responsible for a number of healthcare associated infections, or HAIs. A high percentage of hospital-acquired infections\n",
      "are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative\n",
      "bacteria. We believe the need for novel antibiotics is increasing as a result of the growing resistance of target pathogens to\n",
      "existing FDA approved antibiotics on the market.\n",
      "3037 0  \n",
      "3039 0 Lantibiotics\n",
      "have been difficult to investigate for their clinical usefulness as therapeutic agents in the treatment of infectious diseases\n",
      "due to a general inability to produce or synthesize sufficient quantities of pure amounts of these molecules. Traditional fermentation\n",
      "methods can only produce minute amounts of the lantibiotic.\n",
      "3044 0  \n",
      "3046 0 In\n",
      "June 2012, we entered into the Lantibiotic Exclusive Channel Collaboration agreement (“Lantibiotic ECC”) with Intrexon\n",
      "for the development and commercialization of the native strain of MU1140 and related homologs using Intrexon’s advanced\n",
      "transgene and cell engineering platforms. Through our work with Intrexon, we have been able to produce a significant increase\n",
      "in the fermentation titer of MU1140 compared to standard fermentation methods and have discovered a new purification process for\n",
      "MU1140. Our work with Intrexon generated a substantial number of homologs of MU1140, and we are continuing our research and development\n",
      "and collaboration efforts with Intrexon to develop potential derivatives of the MU1140 molecule using genetically modified bacteria.\n",
      "3054 0  \n",
      "3056 0 None\n",
      "3065 0  \n",
      "3067 0 None\n",
      "3076 0  \n",
      "3078 0 The\n",
      "timing of the filing of an IND regarding OG716 is subject to our having sufficient available capital given all of our anticipated\n",
      "needs and expected requirements in connection with our ongoing research and development initiatives. We expect the IND for a first-in-human\n",
      "clinical study of OG716 to be filed with the FDA following our completion of the requisite studies, which we commenced in October\n",
      "of 2019.\n",
      "3084 0  \n",
      "3086 0 Other\n",
      "Product Candidates and Technologies.\n",
      "3089 0  \n",
      "3091 0 In\n",
      "addition to our lantibiotics and oral mucositis product candidates, we also have other candidates and technologies in the oral\n",
      "care and weight loss areas. We do not intend to continue to develop these potential product candidates and technologies without\n",
      "partnering with a third party. We out-licensed the continued research and development of our weight loss product candidate in\n",
      "December 2013 to, LPThera LLC, and LPThera LLC continues to work to develop a product for commercial use in pets. Our oral care\n",
      "product candidate SMaRT Replacement Therapy is positioned for out-licensing opportunities.\n",
      "3098 0  \n",
      "3106 0  \n",
      "3108 0 Corporate\n",
      "and Other Information\n",
      "3111 0  \n",
      "3113 0 We\n",
      "were incorporated in November 1996 and commenced operations in 1999. We consummated our initial public offering in June 2003.\n",
      "We have devoted substantially all of our available resources to the commercialization of our products as well as our discovery\n",
      "efforts comprising research and development, clinical trials for our product candidates, protection of our intellectual property\n",
      "and the general and administrative support of these operations. We have generated limited revenues from grants and product sales\n",
      "through June 30, 2016, and have principally funded our operations through the sale of debt and equity securities, including the\n",
      "exercise of warrants issued in connection with these financing transactions. In June of 2016, we completed the sale of our consumer\n",
      "probiotics business to ProBiora Health, LLC and as a result, we will no longer generate revenue from sales of consumer probiotic\n",
      "products.\n",
      "3123 0  \n",
      "3125 0 As\n",
      "of September 30, 2019, we had an accumulated deficit of $123,755,548 and we have yet to achieve profitability. We incurred net\n",
      "losses of $11,968,726 and $7,158,521 for the nine months ended September 30, 2019 and 2018, respectively, and we incurred net\n",
      "losses of $9,914,141 and $6,731,525 for the years ended December 31, 2018 and 2017, respectively. We expect to incur significant\n",
      "and increasing operating losses for the foreseeable future as we seek to advance our product candidates through preclinical testing\n",
      "and clinical trials to ultimately obtain regulatory approval and eventual commercialization. We will need to raise additional\n",
      "capital. Adequate additional funding may not be available to us on acceptable terms, or at all. We expect that research and development\n",
      "expenses will increase along with general and administrative costs, as we seek to grow and continue to operate our business. There\n",
      "can be no assurance that additional capital will be available to us on acceptable terms, if at all.\n",
      "3135 0  \n",
      "3137 0 Our\n",
      "executive office is located at, 4902 Eisenhower Boulevard, Suite 125 Tampa, Florida, 33634 and our research facilities are located\n",
      "at 13700 Progress Boulevard, Alachua, Florida 32615. Our telephone number is (813) 286-7900 and our website is http://www.oragenics.com.\n",
      "Information on, or that can be accessed through, our website is not part of this prospectus and should not be relied on in connection\n",
      "with this offering.\n",
      "3143 0  \n",
      "3145 0 For\n",
      "a complete description of our business, financial condition, results of operations and other important information, we refer you\n",
      "to our filings with the Securities and Exchange Commission (the “SEC”) that are incorporated by reference in this\n",
      "prospectus, including our Annual Report on Form 10-K for the year ended December 31, 2018. For instructions on how to find copies\n",
      "of these documents, see “Where You Can Find Additional Information” and “Incorporation of Certain Information\n",
      "by Reference.”\n",
      "3152 0  \n",
      "3160 0  \n",
      "3162 0 None\n",
      "3165 0  \n",
      "3167 0 We\n",
      "may offer shares of our common stock, warrant shares of our common stock to purchase, either individually or in combination, and/or\n",
      "units consisting of some or all of such securities for total gross proceeds of up to $50.0 million, from time to time under this\n",
      "prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms\n",
      "to be determined by market conditions at the time of any offering. This prospectus provides you with a general description of\n",
      "the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus\n",
      "supplement that will describe the specific amounts, prices and other important terms of the securities being offered, including\n",
      "to the extent applicable:\n",
      "3176 0  \n",
      "3234 0  \n",
      "3236 0 The\n",
      "applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also\n",
      "add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no\n",
      "prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus\n",
      "at the time of the effectiveness of the registration statement of which this prospectus is a part.\n",
      "3242 0  \n",
      "3244 0 This\n",
      "prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.\n",
      "3247 0  \n",
      "3249 0 We\n",
      "may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents,\n",
      "reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters\n",
      "or agents, we will include in the applicable prospectus supplement:\n",
      "3254 0  \n",
      "3278 0  \n",
      "3280 0 None\n",
      "3287 0  \n",
      "3289 0 In\n",
      "the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to receive ratably our net assets\n",
      "available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights\n",
      "of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights.\n",
      "There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of holders\n",
      "of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred\n",
      "stock that we may designate and issue in the future.\n",
      "3297 0  \n",
      "3299 0 None\n",
      "3310 0  \n",
      "3312 0 Any\n",
      "warrants issued under this prospectus will be evidenced by warrant certificates. Warrants may be issued under an applicable warrant\n",
      "agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable,\n",
      "in the prospectus supplement relating to the particular series of warrants being offered.\n",
      "3317 0  \n",
      "3325 0 None\n",
      "3327 0  \n",
      "3329 0 None\n",
      "3332 0  \n",
      "3334 0 Investing\n",
      "in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the\n",
      "heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus,\n",
      "and under similar headings in our Annual Report on Form 10-K for the year ended December 31, 2018, as updated by any subsequently\n",
      "filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether to\n",
      "purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each\n",
      "of the risk factors described in the documents referenced above could adversely affect our business, operating results and financial\n",
      "condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks\n",
      "might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe\n",
      "are immaterial may also significantly impair our business operations.\n",
      "3345 0  \n",
      "3353 0  \n",
      "3355 0 None\n",
      "3358 0  \n",
      "3360 0 This\n",
      "prospectus and the documents incorporated by reference herein contain forward-looking statements. These are based on our management’s\n",
      "current beliefs, expectations and assumptions about future events, conditions and results and on information currently available\n",
      "to us. Discussions containing these forward-looking statements may be found, among other places, in the sections entitled “Business,”\n",
      "“Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”\n",
      "contained in the documents incorporated by reference herein.\n",
      "3367 0  \n",
      "3369 0 Any\n",
      "statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future\n",
      "events or performance are not historical facts and are forward-looking statements. Within the meaning of Section 27A of the Securities\n",
      "Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, these forward-looking statements\n",
      "include statements regarding:\n",
      "3375 0  \n",
      "3505 0  \n",
      "3507 0 Except\n",
      "as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking\n",
      "statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available\n",
      "in the future.\n",
      "3512 0  \n",
      "3520 0  \n",
      "3522 0 None\n",
      "3525 0  \n",
      "3527 0 We\n",
      "will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described\n",
      "in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection\n",
      "with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for working\n",
      "capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire\n",
      "businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements\n",
      "with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement\n",
      "or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the\n",
      "prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade,\n",
      "interest-bearing securities.\n",
      "3538 0  \n",
      "3540 0 None\n",
      "3543 0  \n",
      "3545 0 We\n",
      "have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common\n",
      "stock for the foreseeable future. We intend to use all available cash and liquid assets in the operation and growth of our business.\n",
      "Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend\n",
      "upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as our board of\n",
      "directors deems relevant.\n",
      "3552 0  \n",
      "3554 0 Our\n",
      "outstanding shares of Series C, Non-Voting, Non-Convertible, Redeemable Preferred Stock (“Series C Preferred Stock”)\n",
      "with a stated value of $33,847 per share has an accruing dividend payable in additional shares of Series C Preferred Stock. The\n",
      "accruing dividend increased from 12% to 20% per year after May 10, 2019. In January of 2018 and in January of 2019, we paid dividends\n",
      "on our Series C Preferred Stock to Intrexon of 1.733 Series C Preferred shares and 12.208 Series C Preferred shares, respectively.\n",
      "3560 0  \n",
      "3568 0  \n",
      "3570 0 None\n",
      "3573 0  \n",
      "3575 0 The\n",
      "following descriptions are summaries of the material terms that are included in our amended and restated articles of incorporation\n",
      "(as amended) and our bylaws (as amended) as well as the specific agreements such descriptions relate to. This summary is qualified\n",
      "in its entirety by the specific terms and provisions contained in our restated articles of incorporation, bylaws and the specific\n",
      "agreements described herein, copies of which we have filed as exhibits to the registration statement of which this prospectus\n",
      "is a part, and by the provisions of applicable law.\n",
      "3582 0  \n",
      "3584 0 Overview\n",
      "3586 0  \n",
      "3588 0 Authorized\n",
      "Capital Stock\n",
      "3591 0  \n",
      "3593 0 Our\n",
      "authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred\n",
      "stock, without par value. As of November 8, 2019, there were 46,124,803 shares of our common stock issued and outstanding and\n",
      "16,017,113.941 shares of our preferred stock issued and outstanding.\n",
      "3598 0  \n",
      "3600 0 Reverse\n",
      "Stock Split\n",
      "3603 0  \n",
      "3605 0 Our\n",
      "shareholders and Board of Directors approved a one-for-ten reverse stock split which took effect on January 19, 2018. As a result\n",
      "of the reverse stock split every ten shares of our common stock was automatically combined and converted into one issued and outstanding\n",
      "share of our common stock, with no change in the par value per share. All share amounts, per share amounts and share prices in\n",
      "this prospectus supplement have been adjusted to reflect the reverse stock split.\n",
      "3611 0  \n",
      "3613 0 Common\n",
      "Stock\n",
      "3616 0  \n",
      "3618 0 Voting\n",
      "3620 0  \n",
      "3622 0 The\n",
      "holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders.\n",
      "Approval of an amendment of our articles of incorporation, a merger, a share exchange, a sale of all our property or dissolution\n",
      "must be approved by a majority of all votes entitled to be cast. Such votes may be cast in person or by proxy as provided in Article\n",
      "I Section 8 of our bylaws.\n",
      "3628 0  \n",
      "3630 0 Dividends\n",
      "3632 0  \n",
      "3634 0 Our\n",
      "Board of Directors, subject to any restrictions contained in (i) the Florida Business Corporation Act, or FBCA; or (ii) our amended\n",
      "and restated articles of incorporation, as amended, or Articles of Incorporation, may make dividends upon our securities. Distributions\n",
      "may be paid in cash, in property, or in our securities.\n",
      "3639 0  \n",
      "3641 0 We\n",
      "have not declared or paid any dividends on our common stock. We presently intend to retain our future earnings, if any, to fund\n",
      "the development and growth of our business and, therefore, do not have plans to pay any dividends in the foreseeable future.\n",
      "3645 0  \n",
      "3647 0 Other\n",
      "Rights\n",
      "3650 0  \n",
      "3652 0 Upon\n",
      "our liquidation, dissolution or winding-up, after payment in full of our liabilities and the amounts required to be paid to holders\n",
      "of any outstanding shares of preferred stock, if any, all holders of our common stock, along with the holders of our Series A\n",
      "Convertible Preferred Stock and Series B Convertible Preferred Stock on an “as if” converted basis, will be entitled\n",
      "to receive a pro rata distribution of all of our assets and funds legally available for distribution.\n",
      "3658 0  \n",
      "3660 0 No\n",
      "shares of our common stock are subject to redemption or have preemptive rights to purchase additional shares of our common stock\n",
      "or any of our other securities.\n",
      "3664 0  \n",
      "3672 0  \n",
      "3674 0 Fully\n",
      "Paid and Nonassessable\n",
      "3677 0  \n",
      "3679 0 All\n",
      "of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid\n",
      "and nonassessable.\n",
      "3683 0  \n",
      "3685 0 Preferred\n",
      "Stock\n",
      "3688 0  \n",
      "3690 0 Our\n",
      "Board of Directors has the authority, without action by our shareholders, to designate and issue up to 50,000,000 shares of preferred\n",
      "stock in one or more series or classes and to designate the rights, preferences and privileges of each series or class, which\n",
      "may be greater than the rights of our common stock. These rights, preferences and privileges could include dividend rights, conversion\n",
      "rights, voting rights, redemption rights, liquidation preferences, the number of shares constituting any class or series and the\n",
      "designation of the class or series. Terms selected by our board of directors in the future could decrease the amount of earnings\n",
      "and assets available for distribution to holders of shares of common stock or adversely affect the rights and powers, including\n",
      "voting rights, of the holders of shares of common stock without any further vote or action by the stockholders. As a result, the\n",
      "rights of holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of the Series\n",
      "A Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Non-Convertible Preferred Stock or any other\n",
      "preferred stock that may be issued by us in the future, which could have the effect of decreasing the market price of our common\n",
      "stock. As of November 8, 2019, we have 16,017,113.941 shares of preferred stock issued and outstanding.\n",
      "3703 0  \n",
      "3705 0 Series\n",
      "A Convertible Preferred Stock\n",
      "3708 0  \n",
      "3710 0 On\n",
      "May 10, 2017 and on July 25, 2017, we issued an aggregate of 12,000,000 shares of convertible preferred stock, designated as the\n",
      "Series A Convertible Preferred Stock pursuant to the certificate of designation and rights filed by us with the Secretary of State\n",
      "of the State of Florida, with an aggregate original purchase price and initial liquidation preference of $3.0 million. Each share\n",
      "of Series A Convertible Preferred Stock was issued for an amount equal to $0.25 per share, which we refer to as the original purchase\n",
      "price. On March 9, 2018, an investor converted a portion of its Series A Preferred to common stock and, as a result of the conversion,\n",
      "9,417,000 shares of Series A Preferred remain outstanding.\n",
      "3718 0  \n",
      "3720 0 The\n",
      "following description is a summary of the material provisions of the Series A Convertible Preferred Stock and the certificate\n",
      "of designation and rights and does not purport to be complete. This summary is subject to and is qualified by reference to all\n",
      "the provisions of the Series A Convertible Preferred Stock and certificate of designation and rights of Series A Convertible Preferred\n",
      "Stock, including the definitions of certain terms used in the certificate of designation and rights. We urge you to read this\n",
      "document because it, and not this description, defines the rights of a holder of the Series A Convertible Preferred Stock. A copy\n",
      "of the form of certificate of designation and rights that we filed with the Secretary of State of the State of Florida effective\n",
      "May 10, 2017 as amended and restated effective November 8, 2017 has been incorporated by reference as an exhibit to the registration\n",
      "statement of which this prospectus forms a part.\n",
      "3730 0  \n",
      "3732 0 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "3735 0  \n",
      "3737 0 The\n",
      "shares of Series A Convertible Preferred Stock do not have a mandatory redemption date and are not subject to any sinking fund.\n",
      "The shares of Series A Convertible Preferred Stock will remain outstanding indefinitely unless we elect to redeem them under the\n",
      "circumstances described below in “Redemption” or we otherwise repurchase them or they are converted into shares of\n",
      "our common stock as described below under “Conversion Rights.”\n",
      "3743 0  \n",
      "3745 0 Dividends\n",
      "3747 0  \n",
      "3749 0 The\n",
      "shares of Series A Convertible Preferred Stock are entitled to participate in all dividends declared and paid on shares of company\n",
      "common stock on an “as if” converted basis.\n",
      "3753 0  \n",
      "3761 0  \n",
      "3763 0 Liquidation\n",
      "Preference\n",
      "3766 0  \n",
      "3768 0 Upon\n",
      "any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction\n",
      "(as defined in the certificate of designation), the holders of Series A Convertible Preferred Stock shall be entitled to receive\n",
      "out of the assets, the greater of (i) the product of the number of shares of Series A Preferred Stock then held by such holder,\n",
      "multiplied by the original issue price; and (ii) the amount that would be payable to such holder in the liquidation in respect\n",
      "of Common Stock issuable upon conversion of such shares of Series A Preferred Stock if all outstanding shares of Series A Preferred\n",
      "Stock were converted into Common Stock immediately prior to the Liquidation.\n",
      "3776 0  \n",
      "3778 0 Ranking\n",
      "3780 0  \n",
      "3782 0 The\n",
      "Series A Convertible Preferred Stock ranks (i) on par with the Common Stock and Series B Convertible Preferred Stock and junior\n",
      "to Series C Non-Convertible Preferred Stock as to dividend rights and (ii) on par with Series B Convertible Preferred Stock, junior\n",
      "to Series C Non-Convertible Preferred Stock and senior to Common Stock as to rights upon liquidation, dissolution or winding up\n",
      "of the Company, whether voluntarily or involuntarily.\n",
      "3788 0  \n",
      "3790 0 See\n",
      "“Voting Rights—Matters Requiring Approval of Holders of Series A Convertible Preferred Stock” for a description\n",
      "of the types of issuances of equity securities and other securities of our company requiring approval of holders of a majority\n",
      "of shares of Series A Convertible Preferred Stock then outstanding, voting together as a class.\n",
      "3795 0  \n",
      "3797 0 Redemption\n",
      "3799 0  \n",
      "3801 0 To\n",
      "the extent we have funds legally available therefor, at any time after the fifth anniversary of the original issue date of the\n",
      "Series A Convertible Preferred Stock, we have the right to redeem all or any portion of the outstanding shares of Series A Convertible\n",
      "Preferred Stock at the original issue price by providing at least seventy five (75) days written notice of such redemption to\n",
      "all holders of the then outstanding shares of Series A Convertible Preferred Stock.\n",
      "3807 0  \n",
      "3809 0 Conversion\n",
      "Rights\n",
      "3812 0  \n",
      "3814 0 The\n",
      "holders of shares of Series A Convertible Preferred Stock will, at any time, be entitled to convert some or all of their Series\n",
      "A Convertible Preferred Stock into the number of shares of our common stock obtained by dividing the original purchase price of\n",
      "the shares to be converted by the aggregate Series A conversion price (which originally equaled the original purchase price, but\n",
      "is subject to adjustment), which amount we refer to as the conversion price.\n",
      "3820 0  \n",
      "3822 0 The\n",
      "conversion price will be adjustable upon the occurrence of certain events and transactions to prevent dilution as described under\n",
      "“Adjustments to Conversion Price to Prevent Dilution.” Any shares of our common stock issued upon conversion of the\n",
      "shares of Series A Convertible Preferred Stock shall be validly issued, fully paid and non-assessable. The Company shall either\n",
      "pay cash in lieu of fractional shares or round up to the next whole share. The initial conversion price was $0.25 but was adjusted\n",
      "to $2.50 as a result of the Company’s reverse split of 1 for 10 on January 19, 2018. On March 9, 2018, an investor holding\n",
      "Series A Preferred, provided a notice of conversion of a portion of its Series A Preferred Stock into common stock based on the\n",
      "post-split adjusted conversion price.\n",
      "3831 0  \n",
      "3833 0 Adjustments\n",
      "to Conversion Price to Prevent Dilution\n",
      "3836 0  \n",
      "3838 0 The\n",
      "Series A Convertible Preferred Stock is subject to provisions that protect the holders against dilution by adjustment of the conversion\n",
      "price and/or number of shares of common stock issuable upon conversion in certain events such as a subdivision, combination or\n",
      "reclassification of our outstanding common stock.\n",
      "3843 0  \n",
      "3845 0 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series A Convertible Preferred Stock\n",
      "3848 0  \n",
      "3850 0 Except\n",
      "as otherwise required by law, the Series A Convertible Preferred Stock shall have no voting rights. However, as long as any shares\n",
      "of Series A Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority\n",
      "of the then outstanding shares of the Series A Convertible Preferred Stock, (a) alter or change adversely the powers, preferences\n",
      "or rights given to the Series A Convertible Preferred Stock or alter or amend the certificate of designation, (b) amend its articles\n",
      "of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Convertible\n",
      "Preferred Stock, (c) increase the number of authorized shares of Series A Convertible Preferred Stock, or (d) enter into any agreement\n",
      "with respect to any of the foregoing.\n",
      "3859 0  \n",
      "3867 0  \n",
      "3869 0 Registration\n",
      "Rights\n",
      "3872 0  \n",
      "3874 0 The\n",
      "holders of the Series A Convertible Preferred Stock were granted certain demand registration rights and piggyback registration\n",
      "rights with respect to the shares of our Common Stock issuable upon conversion of the Series A Preferred Stock and exercise of\n",
      "their associated warrants, subject to customary cutbacks, blackout periods and other exceptions.\n",
      "3879 0  \n",
      "3881 0 Series\n",
      "B Convertible Preferred Stock\n",
      "3884 0  \n",
      "3886 0 On\n",
      "November 8, 2017, we issued 6,600,000 shares of convertible preferred stock, designated as the Series B Convertible Preferred\n",
      "Stock pursuant to the certificate of designation and rights filed by us with the Secretary of State of the State of Florida, with\n",
      "an aggregate original purchase price and initial liquidation preference of $3.3 million. Each share of Series B Convertible Preferred\n",
      "Stock was issued for an amount equal to $0.50 per share, which we refer to as the original purchase price.\n",
      "3892 0  \n",
      "3894 0 The\n",
      "following description is a summary of the material provisions of the Series B Convertible Preferred Stock and the certificate\n",
      "of designation and rights and does not purport to be complete. This summary is subject to and is qualified by reference to all\n",
      "the provisions of the Series B Convertible Preferred Stock and certificate of designation and rights of Series B Convertible Preferred\n",
      "Stock, including the definitions of certain terms used in the certificate of designation and rights. We urge you to read this\n",
      "document because it, and not this description, defines the rights of a holder of the Series B Convertible Preferred Stock. A copy\n",
      "of the form of certificate of designation and rights that we filed with the Secretary of State of the State of Florida effective\n",
      "November 8, 2017 has been incorporated by reference as an exhibit to the registration statement of which this prospectus forms\n",
      "a part.\n",
      "3904 0  \n",
      "3906 0 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "3909 0  \n",
      "3911 0 The\n",
      "shares of Series B Convertible Preferred Stock do not have a mandatory redemption date and are not subject to any sinking fund.\n",
      "The shares of Series B Convertible Preferred Stock will remain outstanding indefinitely unless we elect to redeem them under the\n",
      "circumstances described below in “Redemption” or we otherwise repurchase them or they are converted into shares of\n",
      "our common stock as described below under “Conversion Rights.”\n",
      "3917 0  \n",
      "3919 0 Dividends\n",
      "3921 0  \n",
      "3923 0 The\n",
      "shares of Series B Convertible Preferred Stock are entitled to participate in all dividends declared and paid on shares of company\n",
      "common stock on an “as if” converted basis.\n",
      "3927 0  \n",
      "3929 0 Liquidation\n",
      "Preference\n",
      "3932 0  \n",
      "3934 0 Upon\n",
      "any liquidation, dissolution or winding-up of the Company (any such event, a “Liquidation”), whether voluntary or\n",
      "involuntary, each holder of shares of Series B Convertible Preferred Stock shall be entitled to receive, after payment to the\n",
      "Series C Non-Convertible Preferred Stock as provided in the Certificate of Designation of Series C Non-Convertible Preferred Stock,\n",
      "but on par with Series A Convertible Preferred Stock and in preference to the holders of Common Stock, an amount of cash equal\n",
      "to the greater of (i) the product of the number of shares of Series B Convertible Preferred Stock then held by such holder, multiplied\n",
      "by the original issue price; and (ii) the amount that would be payable to such holder in the Liquidation in respect of Common\n",
      "Stock issuable upon conversion of such shares of Series B Convertible Preferred Stock if all outstanding shares of Series B Convertible\n",
      "Preferred Stock were converted into Common Stock immediately prior to the Liquidation (disregarding for this purpose any and all\n",
      "limitations of any kind on such conversion).\n",
      "3945 0  \n",
      "3947 0 Ranking\n",
      "3949 0  \n",
      "3951 0 The\n",
      "Series B Convertible Preferred Stock ranks (i) on par with the Common Stock and Series A Convertible Preferred Stock and junior\n",
      "to Series C Non-Convertible Preferred Stock as to dividend rights and (ii) junior to Series C Non-Convertible Preferred Stock,\n",
      "on par with Series A Convertible Preferred Stock and senior to the Common Stock as to distributions of assets upon liquidation,\n",
      "dissolution or winding up of the Corporation, whether voluntarily or involuntarily.\n",
      "3957 0  \n",
      "3965 0  \n",
      "3967 0 See\n",
      "“Voting Rights—Matters Requiring Approval of Holders of Series B Convertible Preferred Stock” for a description\n",
      "of the types of issuances of equity securities and other securities of our company requiring approval of holders of a majority\n",
      "of shares of Series B Convertible Preferred Stock then outstanding, voting together as a class.\n",
      "3972 0  \n",
      "3974 0 Redemption\n",
      "3976 0  \n",
      "3978 0 To\n",
      "the extent we have funds legally available therefor, at any time after the fifth anniversary of the original issue date of the\n",
      "Series B Convertible Preferred Stock, we have the right to redeem all or any portion of the outstanding shares of Series B Convertible\n",
      "Preferred Stock at the original issue price by providing at least seventy five (75) days written notice of such redemption to\n",
      "all holders of the then outstanding shares of Series B Convertible Preferred Stock.\n",
      "3984 0  \n",
      "3986 0 Conversion\n",
      "Rights\n",
      "3989 0  \n",
      "3991 0 The\n",
      "holders of shares of Series B Convertible Preferred Stock will, at any time, be entitled to convert some or all of their Series\n",
      "B Convertible Preferred Stock into the number of shares of our common stock obtained by dividing the original purchase price of\n",
      "the shares to be converted by the aggregate Series B conversion price (which originally equaled the original purchase price, but\n",
      "is subject to adjustment), which amount we refer to as the conversion price and then multiplying such product by two (2).\n",
      "3997 0  \n",
      "3999 0 The\n",
      "conversion price will be adjustable upon the occurrence of certain events and transactions to prevent dilution as described under\n",
      "“Adjustments to Conversion Price to Prevent Dilution.” Any shares of our common stock issued upon conversion of the\n",
      "shares of Series B Convertible Preferred Stock shall be validly issued, fully paid and non-assessable. The Company shall either\n",
      "pay cash in lieu of fractional shares or round up to the next whole share. The initial conversion price was $0.50 but was adjusted\n",
      "to $5.00 as a result of the Company’s reverse split of 1 for 10 on January 19, 2018. No shares of Series B Preferred Stock\n",
      "have been converted as of the date of this Prospectus.\n",
      "4007 0  \n",
      "4009 0 Adjustments\n",
      "to Conversion Price to Prevent Dilution\n",
      "4012 0  \n",
      "4014 0 The\n",
      "Series B Convertible Preferred Stock is subject to provisions that protect the holders against dilution by adjustment of the conversion\n",
      "price and/or number of shares of common stock issuable upon conversion in certain events such as a subdivision, combination or\n",
      "reclassification of our outstanding common stock.\n",
      "4019 0  \n",
      "4021 0 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series B Convertible Preferred Stock\n",
      "4024 0  \n",
      "4026 0 Except\n",
      "as otherwise required by law, the Series B Convertible Preferred Stock shall have no voting rights. However, as long as any shares\n",
      "of Series B Convertible Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority\n",
      "of the then outstanding shares of the Series B Convertible Preferred Stock, (a) amend, alter, repeal, restate or supplement (in\n",
      "each case, whether by reclassification, merger, consolidation, reorganization or otherwise) the certificate of designation in\n",
      "any manner that would adversely affect the holders of the Series B Convertible Preferred Stock, (b) authorize or agree to authorize\n",
      "any increase in the number of shares of Series B Convertible Preferred Stock or issue any additional shares of Series B Convertible\n",
      "Preferred Stock, (c) amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Company which would\n",
      "adversely affect any right, preference, privilege or voting power of the Series B Convertible Preferred Stock or the holders thereof\n",
      "or (d) agree to take any of the foregoing actions.\n",
      "4037 0  \n",
      "4039 0 Registration\n",
      "Rights\n",
      "4042 0  \n",
      "4044 0 The\n",
      "holders of the Series B Convertible Preferred Stock were granted certain demand registration rights and piggyback registration\n",
      "rights with respect to the shares of our Common Stock issuable upon conversion of the Series B Preferred Stock and exercise of\n",
      "their associated warrants, subject to customary cutbacks, blackout periods and other exceptions.\n",
      "4049 0  \n",
      "4057 0  \n",
      "4059 0 None\n",
      "4062 0  \n",
      "4064 0 On\n",
      "November 8, 2017, we issued 100 shares of non-convertible preferred stock, designated as the Series C Non-Voting, Non-Convertible\n",
      "Preferred Stock pursuant to the certificate of designation and rights filed by us with the Secretary of State of the State of\n",
      "Florida, with a stated value and liquidation preference equal to $33,847.9874 per share, which we refer to as the Stated Value.\n",
      "The shares of Series C Non-Voting, Non-Convertible Preferred Stock are entitled to payment-in-kind (“PIK”) dividends\n",
      "thereon at the annual rate of twelve percent (12%) (the “Initial Rate”) of its Stated Value, payable by issuing additional\n",
      "shares of Series C Non-Voting, Non-Convertible Preferred Stock within thirty days after the end of each calendar year, pro-rata\n",
      "for partial years. On January 25, 2018, we paid a dividend on our Series C Preferred Stock to Intrexon of 1.733 shares for the\n",
      "portion of the 2017 fiscal year the Series C Preferred was outstanding and in January of 2019, we paid a dividend on our Series\n",
      "C Preferred Stock to Intrexon of 12.208 shares.\n",
      "4075 0  \n",
      "4077 0 The\n",
      "following description is a summary of the material provisions of the Series C Non-Voting, Non-Convertible Preferred Stock and\n",
      "the certificate of designation and rights and does not purport to be complete. This summary is subject to and is qualified by\n",
      "reference to all the provisions of the Series C Non-Voting, Non-Convertible Preferred Stock and certificate of designation and\n",
      "rights of Series C Non-Voting, Non-Convertible Preferred Stock, including the definitions of certain terms used in the certificate\n",
      "of designation and rights. We urge you to read this document because it, and not this description, defines the rights of a holder\n",
      "of the Series C Non-Voting, Non-Convertible Preferred Stock. A copy of the form of certificate of designation and rights that\n",
      "we filed with the Secretary of State of the State of Florida effective November 8, 2017 has been incorporated by reference as\n",
      "an exhibit to the registration statement of which this prospectus forms a part.\n",
      "4087 0  \n",
      "4089 0 No\n",
      "Mandatory Redemption Date or Sinking Fund\n",
      "4092 0  \n",
      "4094 0 The\n",
      "shares of Series C Non-Voting, Non-Convertible Preferred Stock do not have a mandatory redemption date and are not subject to\n",
      "any sinking fund. The shares of Series C Non-Voting, Non-Convertible Preferred Stock will remain outstanding indefinitely unless\n",
      "we elect to redeem them under the circumstances described below in “Redemption” or we otherwise repurchase them.\n",
      "4099 0  \n",
      "4101 0 Dividends\n",
      "4103 0  \n",
      "4105 0 The\n",
      "shares of Series C Non-Voting, Non-Convertible Preferred Stock are entitled to receive dividends thereon at the annual rate of\n",
      "twelve percent (12%) (the “Initial Rate”) of its Stated Value, payable by issuing additional shares of Series C Non-Voting,\n",
      "Non-Convertible Preferred Stock within thirty days after the end of each calendar year pro-rata for partial years. The Initial\n",
      "Rate shall be subject to increase to twenty percent (20%) automatically after May 10, 2019. In January of 2018 we paid a dividend\n",
      "on our Series C Non-Voting, Non-Convertible Preferred Stock to Intrexon of 1.733 shares for the portion of the 2017 fiscal year\n",
      "the Series C Non-Voting, Non-Convertible Preferred Stock was outstanding. In January of 2019 we paid a dividend on our Series\n",
      "C Non-Voting, Non-Convertible Preferred Stock to Intrexon of 12.208 shares for the full fiscal year of the 2018.\n",
      "4114 0  \n",
      "4116 0 Liquidation\n",
      "Preference\n",
      "4119 0  \n",
      "4121 0 Upon\n",
      "any liquidation, dissolution or winding-up of the Company (any such event, a “Liquidation”), whether voluntary or\n",
      "involuntary, each holder of shares of Series C Non-Voting, Non-Convertible Preferred Stock shall be entitled to receive, in\n",
      "preference to the holders of Common Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and to\n",
      "all other equity securities issued by the Corporation from time to time (the “Junior Securities”), an amount of\n",
      "cash equal to the product of (i) the sum of (a) the number of shares of Series C Non-Voting, Non-Convertible Preferred Stock\n",
      "then held by such holder plus (b) the number of shares of Series C Non-Voting, Non-Convertible Preferred Stock issuable to\n",
      "such holder in connection with any accrued but unpaid dividends, multiplied by (ii) the Stated Value per share of Series C\n",
      "Non-Voting, Non-Convertible Preferred Stock (the “Series C Liquidation Amount”) and no distributions or payments\n",
      "shall be made in respect of any Junior Securities unless all Series C Liquidation Amounts, if any, are first paid in\n",
      "full.\n",
      "4133 0  \n",
      "4141 0  \n",
      "4143 0 Ranking\n",
      "4145 0  \n",
      "4147 0 The\n",
      "Series C Non-Voting, Non-Convertible Preferred Stock ranks (i) senior to the Junior Securities as to dividend rights and (ii)\n",
      "senior to the Junior Securities as to rights upon liquidation, dissolution or winding up of the Corporation, whether voluntarily\n",
      "or involuntarily.\n",
      "4152 0  \n",
      "4154 0 See\n",
      "“Voting Rights—Matters Requiring Approval of Holders of Series C Non-Convertible Preferred Stock” for a description\n",
      "of the types of issuances of equity securities and other securities of our company requiring approval of holders of a majority\n",
      "of shares of Series C Non-Voting, Non-Convertible Preferred Stock then outstanding, voting together as a class.\n",
      "4159 0  \n",
      "4161 0 Redemption\n",
      "4163 0  \n",
      "4165 0 To\n",
      "the extent we have funds legally available therefor, at any time after November 8, 2017, we have the right to redeem all or any\n",
      "portion of the outstanding shares of Series C Non-Voting, Non-Convertible Preferred Stock at the Stated Value by providing at\n",
      "least thirty (30) days written notice of such redemption to all holders of the then outstanding shares of Series C Non-Voting,\n",
      "Non-Convertible Preferred Stock.\n",
      "4171 0  \n",
      "4173 0 No\n",
      "Conversion Rights\n",
      "4176 0  \n",
      "4178 0 The\n",
      "shares of Series C Non-Voting, Non-Convertible Preferred Stock do not have any conversion rights and are not convertible into\n",
      "or exchangeable for any other property or securities of the Company.\n",
      "4182 0  \n",
      "4184 0 Voting\n",
      "Rights—Matters Requiring Approval of Holders of Series C Non-Voting, Non-Convertible Preferred Stock\n",
      "4187 0  \n",
      "4189 0 Except\n",
      "as otherwise required by law, the Series C Non-Voting, Non-Convertible Preferred Stock shall have no voting rights. However, as\n",
      "long as any shares of Series C Non-Voting, Non-Convertible Preferred Stock are outstanding, we shall not, without the affirmative\n",
      "vote of the holders of a majority of the then outstanding shares of the Series C Non-Voting, Non-Convertible Preferred Stock,\n",
      "(a) amend, alter, repeal, restate or supplement (in each case, whether by reclassification, merger, consolidation, reorganization\n",
      "or otherwise) the certificate of designation in any manner that would adversely affect the holders of the Series C Non-Voting,\n",
      "Non-Convertible Preferred Stock, (b) authorize or agree to authorize any increase in the number of shares of Series C Non-Voting,\n",
      "Non-Convertible Preferred Stock or issue any additional shares of Series C Non-Voting, Non-Convertible Preferred Stock, (c) amend,\n",
      "alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Company which would adversely affect any right,\n",
      "preference, or privilege of the Series C Non-Voting, Non-Convertible Preferred Stock or the holders thereof or (d) agree to take\n",
      "any of the foregoing actions.\n",
      "4201 0  \n",
      "4203 0 Series\n",
      "D Preferred Stock-Converted to Common Stock\n",
      "4206 0  \n",
      "4208 0 On\n",
      "July 13, 2018, our board of directors designated 9,364,000 shares of our preferred stock as Series D Convertible Preferred Stock\n",
      "(“Series D Preferred Stock”), which were subsequently issued on July 17, 2018, none of which are currently issued\n",
      "and outstanding. The preferences and rights of the Series D Preferred Stock was set forth in a Certificate of Designation (the\n",
      "“Series D Certificate of Designation”). Pursuant to a transfer agency agreement between us and Continental Stock Transfer&\n",
      "Trust Company, as transfer agent, the Series D Preferred Stock was issued in book-entry form and represented only by one or more\n",
      "global certificates deposited with The Depository Trust Company, or DTC, and registered in the name of Cede & Co., a nominee\n",
      "of DTC, or as otherwise directed by DTC. Prior to the end of 2018, all of 9,364,000 shares of Series D Preferred Stock had converted\n",
      "to common stock and as such, the Company no longer has any Series D Preferred Stock outstanding.\n",
      "4218 0  \n",
      "4226 0  \n",
      "4228 0 Options\n",
      "and Warrants\n",
      "4231 0  \n",
      "4233 0 As\n",
      "of December 27, 2019, there were 26,538,593 shares of common stock issuable upon exercise of warrants to investors at a weighted\n",
      "average exercise price per share of $1.08, 2,488,293 shares issuable upon exercise of options outstanding at a weighted average\n",
      "exercise price of $1.50 per share, and an additional 5,520,957 shares available for option grants under our 2012 Equity Incentive\n",
      "Plan, as amended. The issuance of shares of our common stock under our 2012 Equity Incentive Plan is covered by Form S-8 registration\n",
      "statements we filed with the Securities and Exchange Commission, or SEC, and upon exercise of the options, such shares may be\n",
      "resold into the market. We have also issued shares of common stock and warrants in connection with previous private placements.\n",
      "Such shares are available for resale as well as certain of the shares of common stock issuable upon exercise of the warrants.\n",
      "We have also issued shares of our common stock in private placement and financing transactions, which are deemed to be “restricted\n",
      "securities,” as that term is defined in Rule 144 promulgated under the Securities Act of 1933, as amended, or Securities\n",
      "Act, and such shares may be resold pursuant to the provisions of Rule 144.\n",
      "4245 0  \n",
      "4247 0 Contingent\n",
      "Share Issuance-Intrexon\n",
      "4250 0  \n",
      "4252 0 None\n",
      "4266 0  \n",
      "4268 0 Under\n",
      "the SIA, we also agreed to make certain payments to Intrexon upon our achievement of designated milestones in the form of shares\n",
      "of our common stock (based upon the fair market value of the shares otherwise required to be issued) unless the issuance of such\n",
      "shares would reasonably likely cause Intrexon to consolidate our financial statements with Intrexon’s financial statements,\n",
      "or at our option make a cash payment to Intrexon. The Commercialization Milestone Events and amounts payable are as follows:\n",
      "4274 0  \n",
      "4308 0  \n",
      "4310 0 Equity\n",
      "Participation Right-Intrexon\n",
      "4313 0  \n",
      "4315 0 Pursuant\n",
      "to the Stock Issuance Agreement, Intrexon was also entitled, at its election, to participate in future securities offerings by\n",
      "us that constitute “qualified financings” and purchase securities equal to 30% of the number of shares of common stock\n",
      "or other securities sold in such offering (exclusive of Intrexon’s purchase). For this purpose, a “qualified financing”\n",
      "means a sale of common stock or equity securities convertible into common stock in a public or private offering, raising gross\n",
      "proceeds of at least $1,000,000, where the sale of shares is either registered under the Securities Act of 1933, as amended, at\n",
      "the time of issuance or we agree to register the resale of such shares. Intrexon waived their right to participate in the July\n",
      "2012, June 2016, May 2017 and November 2017, April 2018 and July 2018 Private Placements and did not elect to participate in the\n",
      "March 2019 offering.\n",
      "4325 0  \n",
      "4333 0  \n",
      "4335 0 Registration\n",
      "Rights\n",
      "4338 0  \n",
      "4340 0 None\n",
      "4351 0  \n",
      "4353 0 None\n",
      "4359 0  \n",
      "4361 0 None\n",
      "4368 0  \n",
      "4370 0 The\n",
      "following descriptions are summaries of the material terms that are included in our amended and restated articles of incorporation\n",
      "(as amended) and our bylaws (as amended) as well as the specific agreements such descriptions relate to. This summary is qualified\n",
      "in its entirety by the specific terms and provisions contained in our restated articles of incorporation, bylaws and the specific\n",
      "agreements described herein, copies of which we have filed as exhibits to the registration statement of which this prospectus\n",
      "is a part, and by the provisions of applicable law.\n",
      "4377 0  \n",
      "4379 0 Certain\n",
      "Anti-Takeover Provisions\n",
      "4382 0  \n",
      "4384 0 Florida\n",
      "Law\n",
      "4387 0  \n",
      "4389 0 We\n",
      "are not subject to the statutory anti-takeover provisions under Florida law because in our articles of incorporation we have specifically\n",
      "elected to opt out of both the “control-share acquisitions” (F.S. 607.0902) and the “affiliated transactions”\n",
      "(F.S. 607.0901) statutes. Since these anti-takeover statutes do not apply to a corporation that has specifically elected to opt\n",
      "out of such provisions, we would not be able to invoke the protection of such statutes in the event of a hostile takeover attempt.\n",
      "4395 0  \n",
      "4397 0 Articles\n",
      "of Incorporation and Bylaw Provisions\n",
      "4400 0  \n",
      "4402 0 Our\n",
      "articles of incorporation and bylaws contain provisions that could have an anti-takeover effect. These provisions include\n",
      "4405 0  \n",
      "4442 0  \n",
      "4444 0 These\n",
      "provisions in our articles of incorporation and bylaws could delay or discourage transactions involving an actual or potential\n",
      "change in control of us, including transactions in which shareholders might otherwise receive a premium for their shares over\n",
      "their current prices. Such provisions could also limit the ability of shareholders to approve transactions that shareholders may\n",
      "deem to be in their best interests and could adversely affect the price of our common stock.\n",
      "4450 0  \n",
      "4452 0 Listing\n",
      "of Common Stock\n",
      "4455 0  \n",
      "4457 0 Our\n",
      "common stock is currently listed on the NYSE American under the trading symbol “OGEN.”\n",
      "4460 0  \n",
      "4462 0 Transfer\n",
      "Agent and Registrar\n",
      "4465 0  \n",
      "4467 0 The\n",
      "transfer agent and registrar of our common stock is Continental Stock Transfer & Trust Company, 17 Battery Place, New York,\n",
      "New York 10004, telephone: (212) 509-4000.\n",
      "4471 0  \n",
      "4479 0  \n",
      "4481 0 None\n",
      "4484 0  \n",
      "4486 0 The\n",
      "following description, together with the additional information that we include in any applicable prospectus supplement and in\n",
      "any related free writing prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions\n",
      "of the warrants that we may offer under this prospectus, which may be issued in one or more series. Warrants may be offered independently\n",
      "or in combination with other securities offered by any prospectus supplement. While the terms we have summarized below will apply\n",
      "generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants\n",
      "in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered\n",
      "by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for\n",
      "a particular series of warrants may specify different or additional terms.\n",
      "4496 0  \n",
      "4498 0 Any\n",
      "warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable\n",
      "warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable,\n",
      "in the prospectus supplement relating to the particular series of warrants being offered.\n",
      "4503 0  \n",
      "4505 0 We\n",
      "will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from\n",
      "reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that\n",
      "contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of\n",
      "such warrants. The following description summarizes the material terms and provisions of the warrants and is subject to, and qualified\n",
      "in its entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate,\n",
      "as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus.\n",
      "We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under\n",
      "this prospectus, as well as any related free writing prospectuses, and the complete form of warrant and/or the warrant agreement\n",
      "and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants.\n",
      "4516 0  \n",
      "4518 0 General\n",
      "4520 0  \n",
      "4522 0 We\n",
      "will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including:\n",
      "4525 0  \n",
      "4610 0  \n",
      "4618 0  \n",
      "4663 0  \n",
      "4665 0 Before\n",
      "exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such\n",
      "exercise, including: in the case of warrants to purchase common stock, the right to receive dividends, if any, or, payments upon\n",
      "our liquidation, dissolution or winding up or to exercise voting rights, if any.\n",
      "4670 0  \n",
      "4672 0 Exercise\n",
      "of Warrants\n",
      "4675 0  \n",
      "4677 0 Each\n",
      "warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise\n",
      "price that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement\n",
      "relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised\n",
      "at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants\n",
      "offered thereby. After the close of business on the expiration date, unexercised warrants will become void.\n",
      "4684 0  \n",
      "4686 0 Unless\n",
      "we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering\n",
      "the warrant certificate representing the warrants to be exercised together with specified information, and paying the required\n",
      "amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set forth\n",
      "on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of\n",
      "the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant.\n",
      "4693 0  \n",
      "4695 0 Upon\n",
      "receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate\n",
      "trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will,\n",
      "as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or\n",
      "the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable,\n",
      "will be issued for the remaining warrants.\n",
      "4702 0  \n",
      "4704 0 Governing\n",
      "Law\n",
      "4707 0  \n",
      "4709 0 Unless\n",
      "we otherwise specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and\n",
      "construed in accordance with the laws of the State of New York.\n",
      "4713 0  \n",
      "4715 0 Enforceability\n",
      "of Rights by Holders of Warrants\n",
      "4718 0  \n",
      "4720 0 Each\n",
      "warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation\n",
      "or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for\n",
      "more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable\n",
      "warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make\n",
      "any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant,\n",
      "enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants.\n",
      "4728 0  \n",
      "4736 0  \n",
      "4738 0 None\n",
      "4741 0  \n",
      "4743 0 Units\n",
      "4745 0  \n",
      "4747 0 We\n",
      "may issue units consisting of any combination of our common stock and warrants. We will issue each unit so that the holder of\n",
      "the unit is also the holder of each security included in the unit. As a result, the holder of a unit will have the rights and\n",
      "obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities\n",
      "included in the unit may not be held or transferred separately, at any time or at any time before a specified date.\n",
      "4753 0  \n",
      "4755 0 The\n",
      "summary below and that contained in any prospectus supplement is qualified in its entirety by reference to all of the provisions\n",
      "of the unit agreement and/or unit certificate, and depositary arrangements, if applicable. We urge you to read the applicable\n",
      "prospectus supplements and any related free writing prospectuses related to the units that we may offer under this prospectus,\n",
      "as well as the complete unit agreement and/or unit certificate, and depositary arrangements, as applicable, that contain the terms\n",
      "of the units.\n",
      "4762 0  \n",
      "4764 0 We\n",
      "will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from\n",
      "reports that we file with the SEC, the form of unit agreement and/or unit certificate, and depositary arrangements, as applicable,\n",
      "that contain the terms of the particular series of units we are offering, and any supplemental agreements, before the issuance\n",
      "of such units.\n",
      "4770 0  \n",
      "4772 0 The\n",
      "applicable prospectus supplement, information incorporated by reference or free writing prospectus may describe:\n",
      "4775 0  \n",
      "4813 0  \n",
      "4815 0 The\n",
      "applicable provisions described in this section, as well as those described under “Common Stock” and “Warrants”\n",
      "above, will apply to each unit and to each security included in each unit, respectively\n",
      "4819 0  \n",
      "4827 0  \n",
      "4829 0 None\n",
      "4832 0  \n",
      "4834 0 We\n",
      "can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater\n",
      "detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable\n",
      "trustee, depositary or warrant agent maintain for this purpose as the “holders” of those securities. These persons\n",
      "are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in\n",
      "securities that are not registered in their own names, as “indirect holders” of those securities. As we discuss below,\n",
      "indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect\n",
      "holders.\n",
      "4843 0  \n",
      "4845 0 Book-Entry\n",
      "Holders\n",
      "4848 0  \n",
      "4850 0 We\n",
      "may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities\n",
      "may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary\n",
      "on behalf of other financial institutions that participate in the depositary’s book-entry system. These participating institutions,\n",
      "which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.\n",
      "4856 0  \n",
      "4858 0 Only\n",
      "the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered\n",
      "in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary\n",
      "as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along\n",
      "the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial\n",
      "owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they\n",
      "are not obligated to do so under the terms of the securities.\n",
      "4866 0  \n",
      "4868 0 As\n",
      "a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global\n",
      "security, through a bank, broker or other financial institution that participates in the depositary’s book-entry system\n",
      "or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders,\n",
      "and not legal holders, of the securities.\n",
      "4874 0  \n",
      "4876 0 Street\n",
      "Name Holders\n",
      "4879 0  \n",
      "4881 0 We\n",
      "may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to\n",
      "hold their securities in their own names or in “street name.” Securities held by an investor in street name would\n",
      "be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold\n",
      "only a beneficial interest in those securities through an account he or she maintains at that institution.\n",
      "4887 0  \n",
      "4889 0 For\n",
      "securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers\n",
      "and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any\n",
      "such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they\n",
      "receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or\n",
      "because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not legal holders,\n",
      "of those securities.\n",
      "4897 0  \n",
      "4899 0 Legal\n",
      "Holders\n",
      "4902 0  \n",
      "4904 0 Our\n",
      "obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the\n",
      "legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in\n",
      "street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security\n",
      "or has no choice because we are issuing the securities only in global form.\n",
      "4910 0  \n",
      "4918 0  \n",
      "4920 0 For\n",
      "example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even\n",
      "if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders\n",
      "but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences\n",
      "of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event,\n",
      "we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders\n",
      "contact the indirect holders is up to the legal holders.\n",
      "4928 0  \n",
      "4930 0 Special\n",
      "Considerations for Indirect Holders\n",
      "4933 0  \n",
      "4935 0 If\n",
      "you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are\n",
      "represented by one or more global securities or in street name, you should check with your own institution to find out:\n",
      "4939 0  \n",
      "4975 0  \n",
      "4977 0 Global\n",
      "Securities\n",
      "4980 0  \n",
      "4982 0 A\n",
      "global security is a security that represents one or any other number of individual securities held by a depositary. Generally,\n",
      "all securities represented by the same global securities will have the same terms.\n",
      "4986 0  \n",
      "4988 0 Each\n",
      "security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the\n",
      "name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called\n",
      "the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New\n",
      "York, known as DTC, will be the depositary for all securities issued in book-entry form.\n",
      "4994 0  \n",
      "4996 0 A\n",
      "global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor\n",
      "depositary, unless special termination situations arise. We describe those situations below under “—Special Situations\n",
      "When a Global Security Will Be Terminated.” As a result of these arrangements, the depositary, or its nominee, will be the\n",
      "sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to\n",
      "own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank\n",
      "or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an\n",
      "investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder\n",
      "of a beneficial interest in the global security.\n",
      "5006 0  \n",
      "5008 0 If\n",
      "the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the\n",
      "security will be represented by a global security at all times unless and until the global security is terminated. If termination\n",
      "occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be\n",
      "held through any book-entry clearing system.\n",
      "5014 0  \n",
      "5016 0 Special\n",
      "Considerations for Global Securities\n",
      "5019 0  \n",
      "5021 0 As\n",
      "an indirect holder, an investor’s rights relating to a global security will be governed by the account rules of the investor’s\n",
      "financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an\n",
      "indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.\n",
      "5026 0  \n",
      "5034 0  \n",
      "5036 0 If\n",
      "securities are issued only as global securities, an investor should be aware of the following:\n",
      "5039 0  \n",
      "5091 0  \n",
      "5093 0 There\n",
      "may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible\n",
      "for the actions of any of those intermediaries.\n",
      "5097 0  \n",
      "5099 0 Special\n",
      "Situations When a Global Security Will Be Terminated\n",
      "5102 0  \n",
      "5104 0 In\n",
      "a few special situations described below, a global security will terminate and interests in it will be exchanged for physical\n",
      "certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street\n",
      "name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in\n",
      "securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street\n",
      "name investors above.\n",
      "5111 0  \n",
      "5113 0 Unless\n",
      "we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations\n",
      "occur:\n",
      "5117 0  \n",
      "5137 0  \n",
      "5139 0 The\n",
      "applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to\n",
      "the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and\n",
      "neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct\n",
      "holders.\n",
      "5145 0  \n",
      "5153 0  \n",
      "5155 0 None\n",
      "5158 0  \n",
      "5160 0 We\n",
      "may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public,\n",
      "negotiated transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus\n",
      "may also be effected through the issuance of derivative securities, including without limitation, warrants and subscriptions.\n",
      "We may sell the securities to or through underwriters or dealers, through one or more agents, or directly to one or more purchasers.\n",
      "We may distribute securities from time to time in one or more transactions:\n",
      "5167 0  \n",
      "5212 0  \n",
      "5214 0 A\n",
      "prospectus supplement or supplements will describe the terms of the offering of the securities, including:\n",
      "5217 0  \n",
      "5282 0  \n",
      "5284 0 Only\n",
      "the agents or underwriters named in each prospectus supplement will be agents or underwriters in connection with the securities\n",
      "offered by a prospectus supplement.\n",
      "5288 0  \n",
      "5290 0 Offers\n",
      "to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit\n",
      "offers to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified\n",
      "in a prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for\n",
      "the period of its appointment.\n",
      "5296 0  \n",
      "5298 0 If\n",
      "a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer,\n",
      "as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the\n",
      "time of resale.\n",
      "5303 0  \n",
      "5305 0 If\n",
      "an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed\n",
      "with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the\n",
      "underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the\n",
      "purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting\n",
      "discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation\n",
      "in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they\n",
      "may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a\n",
      "dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer.\n",
      "5315 0  \n",
      "5323 0  \n",
      "5325 0 Any\n",
      "compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions\n",
      "or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters,\n",
      "dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of\n",
      "the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities\n",
      "may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and\n",
      "agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required\n",
      "to make in respect thereof and to reimburse those persons for certain expenses.\n",
      "5334 0  \n",
      "5336 0 Any\n",
      "common stock will be listed on the NYSE American, but any other securities may or may not be listed on a national securities exchange.\n",
      "To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize,\n",
      "maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which\n",
      "involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these\n",
      "persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment\n",
      "option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing\n",
      "securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the\n",
      "offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect\n",
      "of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise\n",
      "prevail in the open market. These transactions may be discontinued at any time.\n",
      "5348 0  \n",
      "5350 0 We\n",
      "may authorize underwriters, dealers or other persons acting as our agents to solicit offers by certain institutions or other suitable\n",
      "purchasers to purchase securities from us at the public offering price set forth in the prospectus supplement, pursuant to delayed\n",
      "delivery contracts providing for payment and delivery on the date stated in each applicable prospectus supplement. Each contract\n",
      "will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less\n",
      "nor more than, the respective amounts stated in each applicable prospectus supplement. Institutions with whom the contracts, when\n",
      "authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational\n",
      "and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts\n",
      "will be subject only to those conditions set forth in each applicable prospectus supplement and include the condition that the\n",
      "purchase of the securities covered by the delayed delivery contracts will not at the time of delivery be prohibited under the\n",
      "laws of any jurisdiction in the United States to which the purchaser is subject. Each prospectus supplement will set forth any\n",
      "commissions we pay for solicitation of these contracts. The underwriters and agents will not have any responsibility with respect\n",
      "to the validity or performance of these contracts.\n",
      "5364 0  \n",
      "5366 0 All\n",
      "securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents\n",
      "or underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making\n",
      "at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is currently no\n",
      "market for any of the offered securities, other than our common stock which is listed on the on the NYSE American. Any common\n",
      "stock will be listed on the NYSE American but any other securities may or may not be listed on a national securities exchange.\n",
      "We have no current plans for listing of the, warrants on any securities exchange or quotation system; any such listing with respect\n",
      "to any particular warrants will be described in the applicable prospectus supplement or other offering materials, as the case\n",
      "may be.\n",
      "5376 0  \n",
      "5378 0 Any\n",
      "agents and underwriters who are qualified market makers on the NYSE American may engage in passive market making transactions\n",
      "in the securities on the NYSE American in accordance with Regulation M, during the business day prior to the pricing of the offering,\n",
      "before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price\n",
      "limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price\n",
      "not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker’s\n",
      "bid, however, the passive market maker’s bid must then be lowered when certain purchase limits are exceeded. Passive market\n",
      "making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market\n",
      "and, if commenced, may be discontinued at any time.\n",
      "5388 0  \n",
      "5396 0  \n",
      "5398 0 We\n",
      "may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act.\n",
      "In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to\n",
      "third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those\n",
      "derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including\n",
      "in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those\n",
      "sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives\n",
      "to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not\n",
      "identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition,\n",
      "we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities\n",
      "short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer\n",
      "its economic short position to investors in our securities or in connection with a concurrent offering of other securities.\n",
      "5411 0  \n",
      "5413 0 The\n",
      "specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.\n",
      "5416 0  \n",
      "5418 0 The\n",
      "underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business\n",
      "for which they receive compensation.\n",
      "5422 0  \n",
      "5424 0 In\n",
      "compliance with guidelines of the Financial Industry Regulatory Authority, Inc., or FINRA, the maximum compensation to be received\n",
      "by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant\n",
      "to this prospectus and any applicable prospectus supplement.\n",
      "5429 0  \n",
      "5437 0  \n",
      "5439 0 None\n",
      "5442 0  \n",
      "5444 0 Unless\n",
      "otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity\n",
      "of the securities offered by this prospectus, and any supplement thereto, will be passed upon for us by Shumaker, Loop & Kendrick,\n",
      "LLP.\n",
      "5449 0  \n",
      "5451 0 None\n",
      "5453 0  \n",
      "5455 0 The\n",
      "audited financial statements of Oragenics, Inc. as of December 31, 2018 and 2017, and for the two-year period ended December 31,\n",
      "2018, included in our Annual Report on Form 10-K for the year ended December 31, 2018, incorporated by reference in this prospectus\n",
      "have been audited by Mayer Hoffman McCann P.C., an independent registered public accounting firm, as stated in their report dated\n",
      "March 29, 2019, which is incorporated by reference herein, and has been so incorporated in reliance upon the report of such firm\n",
      "given upon their authority as experts in accounting and auditing.\n",
      "5462 0  \n",
      "5464 0 None\n",
      "5467 0  \n",
      "5469 0 This\n",
      "prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information\n",
      "set forth in the registration statement and the exhibits to the registration statement. For further information with respect to\n",
      "us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules\n",
      "filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated\n",
      "by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making\n",
      "an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this\n",
      "prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery\n",
      "of this prospectus or any sale of the securities offered by this prospectus.\n",
      "5479 0  \n",
      "5481 0 None\n",
      "5485 0  \n",
      "5487 0 None\n",
      "5492 0  \n",
      "5500 0  \n",
      "5502 0 None\n",
      "5505 0  \n",
      "5507 0 The\n",
      "SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information\n",
      "to you by referring you to another document that we have filed separately with the SEC. You should read the information incorporated\n",
      "by reference because it is an important part of this prospectus. We incorporate by reference the following information or documents\n",
      "that we have filed with the SEC, excluding any portions of any Current Report on Form 8-K that are not deemed “filed”\n",
      "pursuant to the General Instructions of Form 8-K:\n",
      "5514 0  \n",
      "5565 0  \n",
      "5567 0 Any\n",
      "information in any of the foregoing documents will automatically be deemed to be modified or superseded to the extent that information\n",
      "in this prospectus or in a later filed document that is incorporated or deemed to be incorporated herein by reference modifies\n",
      "or replaces such information.\n",
      "5572 0  \n",
      "5574 0 We\n",
      "also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K\n",
      "and exhibits filed on such form that are related to such items) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d)\n",
      "of the Exchange Act, including those made after the date of filing of the initial registration statement and prior to effectiveness\n",
      "of the registration statement, until we file a post-effective amendment that indicates the termination of the offering of the\n",
      "securities made by this prospectus. Information in such future filings updates and supplements the information provided in this\n",
      "prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in\n",
      "any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent\n",
      "that statements in the later filed document modify or replace such earlier statements.\n",
      "5584 0  \n",
      "5586 0 We\n",
      "will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or\n",
      "oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered\n",
      "with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You may request\n",
      "a copy of these filings at no cost, by writing to or telephoning us at the following address: Oragenics, Inc., 4902 Eisenhower\n",
      "Boulevard, Suite 125, Tampa, Florida 33634, Attention: Corporate Secretary.\n",
      "5593 0  \n",
      "5601 0  \n",
      "5603 0 None\n",
      "5607 0  \n",
      "5609 0  \n",
      "5611 0  \n",
      "5613 0 None\n",
      "5615 0  \n",
      "5617 0 None\n",
      "5620 0  \n",
      "5622 0  \n",
      "5624 0 None\n",
      "5628 0  \n",
      "5630 0 PROSPECTUS\n",
      "SUPPLEMENT\n",
      "5633 0  \n",
      "5635 0 None\n",
      "5639 0  \n",
      "5641 0  \n",
      "5643 0  \n",
      "5645 0  \n",
      "5647 0 None\n",
      "5650 0  \n",
      "5652 0  \n",
      "5654 0  \n",
      "5656 0  \n",
      "5658 0 A.G.P.\n",
      "5660 0  \n",
      "5662 0  \n",
      "5664 0  \n",
      "5666 0  \n",
      "5668 0 None\n",
      "5672 0  \n",
      "5679 0 None\n"
     ]
    }
   ],
   "source": [
    "for line in soup.find_all('p'):\n",
    "    print(line.sourceline, line.sourcepos,line.string)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Apparently sections in the document that are next to each other have very different sourcelines and positions. Maybe all 'a' tags are grouped, and the same with all other types of tags."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "## maybe try this again but using re.finditers? "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
